

FORM PTO-1390 (REV 12-29-99)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 2549US0P
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>097787658</b>
INTERNATIONAL APPLICATION NO. PCT/JP99/05216	INTERNATIONAL FILING DATE September 24, 1999	PRIORITY DATE CLAIMED September 25, 1998	
TITLE OF INVENTION Peptide Derivative			
APPLICANT(S) FOR DO/EO/US Chieko KITADA et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). *</li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11. to 16. below concern document(s) or information included:			
<ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> <li>1) Sequence Listing (Paper &amp; Computer-readable copies)</li> <li>2) Sequence Listing Statement</li> </ol> </li> </ol>			
<p>* This includes specification 116 total pages, including Claims 1-28 (5 pgs), Abstract (1 pg), Sequence listing (17 pgs) and Drawings (1 pg).</p>			

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>097787658</b>		INTERNATIONAL APPLICATION NO. PCT/JP99/05216		ATTORNEY'S DOCKET NUMBER 2549USOP	
---	--	---	--	--------------------------------------	--

<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p><b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b></p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$970.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$690.00</b></p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$670.00</b></p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$96.00</b></p> <p style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></p> <p>Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:15%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:25%;"></th> </tr> <tr> <td>Total claims</td> <td>28 - 20 =</td> <td>8</td> <td>X \$18.00</td> <td>\$ 144.00</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>X \$ 80.0</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$260.00</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td>\$ 1004.00</td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>SUBTOTAL =</b></td> <td>\$ 1004.00</td> </tr> <tr> <td colspan="4">Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL NATIONAL FEE =</b></td> <td>\$ 1004.00</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property</td> <td>+ \$ 40.00</td> </tr> <tr> <td colspan="4" style="text-align: right;"><b>TOTAL FEES ENCLOSED =</b></td> <td>\$ 1044.00</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded: \$</td> </tr> <tr> <td colspan="4"></td> <td>charged: \$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	28 - 20 =	8	X \$18.00	\$ 144.00	Independent claims	1 - 3 =	0	X \$ 80.0	\$ 0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$260.00	<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1004.00	Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	<b>SUBTOTAL =</b>				\$ 1004.00	Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	<b>TOTAL NATIONAL FEE =</b>				\$ 1004.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property				+ \$ 40.00	<b>TOTAL FEES ENCLOSED =</b>				\$ 1044.00					Amount to be refunded: \$					charged: \$	<p><b>CALCULATIONS PTO USE ONLY</b></p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																															
Total claims	28 - 20 =	8	X \$18.00	\$ 144.00																																																														
Independent claims	1 - 3 =	0	X \$ 80.0	\$ 0.00																																																														
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$260.00																																																														
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1004.00																																																														
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$																																																														
<b>SUBTOTAL =</b>				\$ 1004.00																																																														
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																																																														
<b>TOTAL NATIONAL FEE =</b>				\$ 1004.00																																																														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property				+ \$ 40.00																																																														
<b>TOTAL FEES ENCLOSED =</b>				\$ 1044.00																																																														
				Amount to be refunded: \$																																																														
				charged: \$																																																														

a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 500799 in the amount of \$ 1044.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 500799. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Customer No. 23,115

Philippe Y. Riesen, Reg. No. 35,657  
Mark Chao, Ph.D., Reg. No. 37,293

Date: March 15, 2001

SPECIFICATION  
Peptide Derivatives

FIELD OF THE INVENTION

5       The present invention relates to novel peptides that are orphan G protein-coupled receptor proteins and have ligand activities for APJ, and their use.

BACKGROUND ART

10       Many hormones or neurotransmitters regulate biological functions through specific receptors that exist on the cell membranes. These receptors are generically called G  
15       protein-coupled receptors or 7 transmembrane receptors, since many of them perform intracellular signal transduction by the activation of conjugated guanine nucleotide-binding proteins (abbreviated as G protein in some cases) and have common structures with 7 membrane domains.

20       Through interactions between these hormones or neurotransmitters and G protein-coupling receptors, the regulation of functions which are important for organisms are conducted, including the maintenance of homeostasis, the regulation of reproduction, individual development, metabolism, growth, nervous system, circulatory system, immune system, digestive system, and metabolic system. Although it  
25       has been known that receptor proteins for various hormones or neurotransmitters exist in regulating biological functions and play important roles in the regulation of those functions, it is unclear whether there are unknown active substances such as hormones or neurotransmitters, or corresponding receptors.

30       It has been found in recent years that DNAs, which code novel receptor proteins, can be searched by the polymerase chain reaction method (hereinafter abbreviated as PCR), taking advantage of the similarity of the amino acid sequence indicated in a part of the structures of G protein-coupled receptor  
35       proteins. This has enabled the cloning of a large number of so-called orphan G protein-coupled receptor proteins, for which

ligands are unknown (Libert, F., et al., Science, 244, 569-572, 1989, Welch, S.K., et al., Biochem. Biophys. Res. Commun., 209, 606-613, 1995, Marchese, A., et al., Genomics, 23, 609-618, 1994, Marchese, A., Genomics, 29 335-344, 1995). Furthermore, novel  
5 G protein-coupled receptor proteins are found one after another by random sequencing of genome DNA or cDNA (Nomura, N., et al., DNA Research Vol. 1, 27-35, 1994). There has been no common method for determining ligands of these orphan G  
10 protein-coupled receptor proteins other than to estimate them based on the similarity in the primary structure of G protein-coupled receptor proteins. In practice, however, many orphan G protein-coupled receptor proteins showed low sequence  
15 homology with known receptors, and therefore it has been difficult to estimate the ligand simply from the similarity in the primary structure unless it was a receptor subtype of a known ligand. It is assumed that many corresponding unknown ligands exist since many orphan G protein-coupled receptor proteins have been found in gene analysis, but only a small number of ligands for orphan G protein-coupled receptor proteins have  
20 actually been identified so far.

Recently, some studies have been reported that searched for novel opioid peptides by transferring cDNAs that code orphan G protein-coupled receptor proteins into animal cells (Reinsheid, R. K. et al., Science, Vol. 270, 792-794, 1995;  
25 Menular, J.-C., et al., Nature Vol. 377, 532-535, 1995). However, in this case, it could easily be predicted that the ligand would belong to the opioid peptide family, based on its similarity to known G protein-coupled receptor proteins and the distribution in tissues. Research and development on  
30 substances that act upon biological organisms through opioid peptides have a long history, and various antagonists and agonists have been developed. Therefore, after identifying agonists for this receptor among a series of artificially synthesized compounds and verifying the expression of a  
35 receptor in receptor cDNA transferred cells using such an agonist as the probe, the activator of intracellular signal

transduction system that is similar to agonists was identified and purified to determine the structure of ligands.

It has been reported that a novel physiologically active peptide was identified with the specific increase in the intracellular free calcium levels in receptor expressing cells as the indicator by transferring cDNAs that code orphan G protein-coupled receptor proteins (GRL104) of snails into CHO cells (Cox, K. J. A., et al., Neurosci., 17(4), 1197-1205, 1997). This physiologically active peptide had high homology with known leucokinins and GRL104 was found reactive to known leucokinins. Thus, there rarely were orphan G protein-coupled receptor proteins of which ligands could be roughly predicted, and when the similarity to known G protein-coupled receptor protein family was low, in particular, there has been very limited information about ligands and it has been difficult to predict the ligand.

One of those reported as orphan G protein-coupled receptors is APJ (O'Dowd, B.F., et al., Gene, 436, 355-359, 1993). APJ has low homology with the angiotensin receptor (AT1). Although a natural ligand to APJ and its partial peptide sequence were described in WO 99/33976 (Japanese Patent Application No. 220853-1998), artificially modified natural ligands, such as natural ligands with one or more constituent amino acids substituted by other amino acids or those with side chains of one or more constituent amino acids substituted by appropriate substituents are completely unknown.


#### DISCLOSURE OF THE INVENTION

Peptides that have been artificially modified natural ligands to APJ, an orphan G protein-coupled receptor expressed in the central nervous system, the circulatory system, the reproductive system, the immune system or digestive organs, are considered to be more useful for pharmaceuticals compared to natural ligands, while the structure and function of peptides that are more useful as pharmaceuticals compared to natural ligands have not been demonstrated yet.

In consideration of such problems, the inventors synthesized various novel peptides by using a change in binding properties between modified product of said natural ligands and receptor proteins described above as the indicator and found modified natural ligands that are more useful as pharmaceuticals by predicting and specifying active sites of natural ligands.

Namely, the present invention relates to:

(1) A peptide represented by the formula:



[wherein  $X^1$  represents a hydrogen atom or an amino acid residue comprising 1 to 25 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain;  $X^2$  represents a neutral amino acid residue having a side chain which may be substituted;  $X^3$  represents a neutral amino acid residue having a side chain which may be substituted, an aromatic amino acid residue having a side chain which may be substituted or a basic amino acid residue having a side chain which may be substituted;  $X^4$  represents a bond or a neutral or aromatic amino acid residue having a side chain which may be substituted;  $X^5$  represents ① an amino acid residue having a side chain which may be substituted or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ② a hydroxyl group or ③ a dipeptide chain comprising an amino acid residue having a side chain which may be substituted and an amino acid residue having a side chain which may be substituted, bound together, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group; and a side chain in each amino acid residue in -Arg-Pro-Arg-, -Ser-His- or -Gly-Pro- in the formula may be substituted; except the case where  $X^2$  represents Leu,  $X^3$  represents Lys,  $X^4$  represents Met,  $X^5$  represents ① Pro or ② Pro-Phe, and -Arg-Pro-Arg- in the formula represents unsubstituted -Arg-Pro-Arg-, -Ser-His- represents unsubstituted -Ser-His-, and -Gly-Pro- represents

unsubstituted -Gly-Pro-] or an ester thereof (hereinafter may be abbreviated as peptides of the present invention), or their salt.

(2) A peptide, as described in (1) above, wherein  $X^1$  is an amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(3) A peptide as described in (1) above, wherein  $X^1$  is pGlu which may be substituted or Gln having a side chain which may be substituted, or an ester thereof or their salt.

(4) A peptide as described in (1) above, wherein  $X^1$  is represented by the formula  $Y^1-Y^2$  (wherein  $Y^1$  represents an amino acid residue comprising 1 to 17 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain, and  $Y^2$  represents an amino acid residue comprising 1 to 8 amino acids each of which, whether identical or not, has a side chain which may be substituted or a peptide chain), or an ester thereof or their salt.

(5) A peptide as described in (4) above, wherein  $Y^2$  is a peptide chain represented by ① the formula  $B^1-B^2-B^3-B^4-B^5-B^6-B^7-B^8$  (wherein each of  $B^1$  through  $B^8$ , whether identical or not, represents an amino acid residue having a side chain which may be substituted) ② the formula  $B^2-B^3-B^4-B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as given above), ③ the formula  $B^3-B^4-B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ④ the formula  $B^4-B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ⑤ the formula  $B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ⑥ the formula  $B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ⑦ the formula  $B^7-B^8$ , wherein the symbols have the same definitions as those given above), or ⑧ the formula  $B^8$  (wherein  $B^8$  has the same definition as that given above), or an ester thereof or their salt.

(6) A peptide as described in (5) above, wherein  $B^1$  is a neutral amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(7) A peptide as described in (6) above, wherein  $B^1$  is Gly which may be substituted, or an ester thereof or their salt.

(8) A peptide as described in (5) above, wherein each of  $B^2$ ,  $B^3$  and  $B^4$ , whether identical or not, is a basic amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(9) A peptide as described in (5) above, wherein  $B^5$  is an amino acid residue having an aromatic side chain, or an ester thereof or their salt.

(10) A peptide as described in (5) above, wherein each of  $B^6$  and  $B^7$ , whether identical or not, is a basic amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(11) A peptide as described in (5) above, wherein  $B^8$  is Gln having a side chain which may be substituted, or an ester thereof or their salt.

(12) A peptide as described in (4) above, wherein  $Y^1$  is an amino acid residue or peptide chain represented by (a) the formula  $A^1-A^2-A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein each of  $A^1$  to  $A^{17}$ , whether identical or not, represents an amino acid residue having a side chain which may be substituted), (b) the formula  $A^2-A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (c) the formula

$A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (d) the formula  $A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (e) the formula

$A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (f) the formula  $A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (g) the formula  $A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (h) the formula  $A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the



same definitions as those given above), (i) the formula  $A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (j) the formula  $A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (k) the formula  $A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$ , wherein the symbols have the same definitions as those given above), (l) the formula  $A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (m) the formula  $A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (n) the formula  $A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (o) the formula  $A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (p) the formula  $A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), or (q)  $A^{17}$  (wherein  $A^{17}$  has the same definitions as that given above), or an ester thereof or their salt.

(13) An amino acid residue, or peptide as described in (12) above, wherein  $A^1$  is an amino acid residue having an aromatic side chain, or an ester thereof or their salt.

(14) A peptide as described in (12) above, wherein  $A^2$  and  $A^3$  are neutral amino acid residues having a side chain which may be substituted, or an ester thereof or their salt.

(15) A peptide as described in (12) above, wherein  $A^4$  is a neutral or a basic L-amino acid residue having a side chain is optionally substituted.

(16) A peptide as described in (12) above, wherein  $A^5$  is Pro having a side chain which may be substituted, or an ester thereof or their salt.

(17) A peptide as described in (12) above, wherein each of  $A^6$  and  $A^9$ -, whether identical or not, is a basic amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(18) A peptide as described in (12) above, wherein each of  $A^7$  and  $A^{10}$ -, whether identical or not, is an amino acid residue having a hydroxy group in a side chain thereof or a neutral amino

acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(19) A peptide as described in (12) above, wherein A<sup>8</sup> is an amino acid residue having a hydroxy group in a side chain thereof, or an ester thereof or their salt.

(20) A peptide as described in (12) above, wherein A<sup>8</sup> is Ser, Pro or Hyp, or an ester thereof or their salt.

(21) A peptide as described in (12) above, wherein A<sup>10</sup> is an amino acid residue having a hydroxy group in a side chain thereof, or an ester thereof or their salt.

(22) A peptide as described in (12) above, wherein A<sup>11</sup> through A<sup>14</sup>, whether identical or not, is a neutral amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(23) A peptide as described in (12) above, wherein A<sup>15</sup> is an amino acid residue having an aromatic side chain, or an ester thereof or their salt.

(24) A peptide as described in (23) above, wherein A<sup>15</sup> is Trp, or an ester thereof or their salt.

(25) An amino acid residue or peptide as described in (12) above, wherein each of A<sup>16</sup> and A<sup>17</sup>, whether identical or not, represents a neutral amino acid residue having a side chain which may be substituted, or an ester thereof or their salt.

(26) A pharmaceutical containing a peptide, as described in (1) above, or an ester thereof or their salt.

(27) A pharmaceutical as described in (26) above which is a central nervous function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive function regulator, a metabolic function regulator or a reproductive organ function regulator.

(28) A pharmaceutical as described in (26) above which is an agonist of a protein containing an amino acid sequence shown by Sequence ID No.:26 or a salt thereof.

Additionally, the present invention provides:

(29) Pharmaceuticals or the like described in (26) above that are therapeutic or prophylactic drugs against disorders, such

as: dementia, depression, ADHD

(attention-deficit-hyperactivity disorder; minimal brain dysfunction) syndrome, disturbance of consciousness, anxiety disorder, schizophrenia, phobia, growth hormone secretion disorder, hyperphagia, polyphagia, hypercholesterolemia, hyperglyceridemia, hyperlipidemia, hyperprolactinemia, diabetes, cancer, pancreatitis, renal diseases, Turner's syndrome, neuropathy, rheumatoid arthritis, spinal cord injury, transient ischemic attack, amyotrophic lateral sclerosis, acute myocardial infarct, spinocerebellar degeneration, fracture, injury, atopic dermatitis, osteoporosis, asthma, epilepsy, infertility, arteriosclerosis, emphysema pulmonum, pulmonary edema, hypogalactia or AIDS.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows changes in Acidification Rates of peptides in Examples 3 and 4, and of corresponding natural peptides in Example 1.

In this figure, ▲-▲ shows the amount of changes in Acidification Rates of peptides obtained in Examples 3, □-□ shows those of peptides obtained in Examples 4, and ●-● shows those of corresponding natural peptides in Example 1.

#### BEST MODE OF EMBODIMENT OF THE INVENTION

In the present invention, an amino acid residue refers to the structure of the part other than N- or C-terminals when amino acids form peptide bonds and are incorporated into proteins or peptides by losing water molecules. For example, an  $\alpha$ -amino acid residue refers to the structure of  $\text{-NHC(R}^0\text{)(R}^1\text{)CO-}$  other than N- or C-terminals when  $\alpha$ -amino acid ( $\text{H}_2\text{NC(R}^0\text{)(R}^1\text{)COOH}$ :  $\text{R}^0$  and  $\text{R}^1$ , whether identical or not, represents an optional substituent), forms peptide bond and is incorporated into proteins or peptides by losing water molecules. In this case, an amino acid residue at the N-terminal is represented by  $\text{H}_2\text{NC(R}^0\text{)(R}^1\text{)CO-}$  and at the C-terminal as  $\text{-NHC(R}^0\text{)(R}^1\text{)COOH}$ . Similarly, a  $\beta$ -amino acid residue refers to the structure of

-NHC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)CO- other than N- or C-terminals when  
 β-amino acid (H<sub>2</sub>NC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)COOH: R<sup>0</sup>, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>,  
 whether identical or not, represents an optional substituent)  
 forms peptide bonds and is incorporated into proteins or  
 peptides by losing water molecules. In this case, an amino acid  
 residue at the N-terminal is represented by

H<sub>2</sub>NC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)CO- and at the C-terminal as  
 -NHC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)COOH. Moreover, a γ-amino acid residue  
 refers to the structure of -NHC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)CO-  
 other than N- or C-terminals when ε-amino acid

(H<sub>2</sub>NC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)COOH: R<sup>0</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup>,  
 whether identical or not, represents an optional substituent)  
 forms peptide bonds and is incorporated into proteins or  
 peptides by losing water molecules. In this case, an amino acid  
 residue at the N-terminal is represented by

H<sub>2</sub>NC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)CO- and at the C-terminal as  
 -NHC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)COOH. Moreover, an ε-amino acid  
 residue refers to the structure of

-NHC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)C(R<sup>6</sup>)(R<sup>7</sup>)C(R<sup>8</sup>)(R<sup>9</sup>)CO- other than

N- or C-terminals when ε-amino acid  
 (H<sub>2</sub>NC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)C(R<sup>6</sup>)(R<sup>7</sup>)C(R<sup>8</sup>)(R<sup>9</sup>)COOH: R<sup>0</sup>, R<sup>1</sup>, R<sup>2</sup>,  
 R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup>, whether identical or not, represents  
 an optional substituent) forms peptide bonds and is  
 incorporated into proteins or peptides by losing water

molecules. In this case, an amino acid residue at the  
 N-terminal is represented by

H<sub>2</sub>NC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)C(R<sup>6</sup>)(R<sup>7</sup>)C(R<sup>8</sup>)(R<sup>9</sup>)CO- and at the  
 C-terminal as

-NHC(R<sup>0</sup>)(R<sup>1</sup>)C(R<sup>2</sup>)(R<sup>3</sup>)C(R<sup>4</sup>)(R<sup>5</sup>)C(R<sup>6</sup>)(R<sup>7</sup>)C(R<sup>8</sup>)(R<sup>9</sup>)COOH.

In this specification, an amino acid is a natural or  
 non-natural amino acid that may be either D- or L-configuration,  
 and also be of either type α, β, γ, or ε.

Groups that form the side chains of α-amino acids, β-amino  
 acids, γ-amino acids, or ε-amino acids include:

(1) C<sub>1-6</sub> alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl,  
 n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and

preferably C<sub>1-3</sub> alkyl); (2) cyano group; (3) halogen (e.g. fluorine, chlorine, bromine, and iodine); (4) hydroxy-C<sub>1-6</sub> alkyl group (e.g. hydroxymethyl, and hydroxyethyl); (5) C<sub>1-6</sub> alkoxy group (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, and preferably C<sub>1-3</sub> alkoxy); (6) C<sub>1-6</sub> alkoxy-carbonyl group (e.g. methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, and preferably C<sub>1-3</sub> alkoxy-carbonyl); (7) C<sub>1-4</sub> acyl group (e.g. formyl such as formyl, acetyl, propionyl and butyryl, and C<sub>2-4</sub> alkanoyl); (8) hydroxy group; (9) groups represented by the formula: -S(O)<sub>a</sub>-R<sup>21</sup> [where: a represents an integer between 0 and 2; R<sup>21</sup> represents C<sub>1-6</sub> alkyl (specific examples are the same as the above)] such as methylthio, methanesulfinyl, methanesulfonyl, ethylthio, ethanesulfinyl, ethanesulfonyl; (10) benzyloxycarbonyl; (11) tosyl group; (12) carbamoyl group; (13) mercapto group; (14) amino group; (15) sulfo group; (16) phosphono group; (17) phospho group; (18) carboxyl group; (19) tetrazolyl group; (20) amino-C<sub>1-6</sub> alkyl group (e.g. amino methyl, amino ethyl); (21) amino allyl group; (22) thiazolyl group; (23) thienyl group; (24) oxazolyl group; (25) furyl group; (26) pyranlyl group; (27) pyridyl group; (28) pyrazyl group; (29) pyrazinyl group; (30) pyrimidinyl group; (31) pyridazinyl group; (32) indolyl group; (33) indodinyl group; (34) isoindolyl group; (35) pyrrolyl group; (36) imidazolyl group; (37) isothiazolyl group; (38) pyrazolyl group; (39) chromenyl group; (40) purinyl group; (41) quinolizinylyl group; (42) quinolyl group; (43) isoquinolyl group; (44) quinazolinyl group; (45) quinoxalinyl group; (46) cinnolinyl group; (47) morpholinyl group; (48) benzothienyl group; (49) benzofuranyl group; (50) benzimidazolyl; (51) benzimidazolyl group; (52) C<sub>3-8</sub> cycloalkyl group; (53) C<sub>1-4</sub> alkyl group substituted by the substituents described in (2), (3), (5) to (17), and (20) to (52) above; (54) C<sub>1-4</sub> acyl group, such as formyl and C<sub>2-4</sub> alkanoyl, substituted by the substituents described in (2), (3), (5) to (17), and (20) to (52) above; (55) C<sub>6-10</sub> aryl group such as phenyl substituted by the substituents described in (1) to (52) above (e.g. mesityl, tolyl, xylyl,

styrenyl); (56)  $C_{7-15}$  aralkyl group such as benzyl substituted by the substituents described in (1) to (52) above (e.g. methylbenzyl methoxybenzyl); (57)  $C_{7-15}$  aralkyl group (e.g. benzyl, phenethyl, benzhydryl, naphthylmethyl); (58)  $C_{6-10}$  aryl group (e.g. phenyl, naphthyl, indenyl); and (59) hydrogen atom.

The side chain that forms an amino acid residue and a nitrogen atom can bind together to form a ring (e.g. proline), or two side chains can bind together to form a ring (e.g. 3-amino-norbornane-carboxylic acid).

Examples of  $\alpha$ -amino acid include glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, lysine, arginine, phenylalanine, tyrosine, histidine, tryptophan, asparagine, glutamine, proline, pipercolic acid, norleucine,  $\gamma$ -methyllleucine, tert-leucine, norvaline, homoarginine, homoserine,  $\alpha$ -aminoisobutyric acid,  $\alpha$ -aminobutyric acid, ornithine,  $\alpha$ -aminoadipic acid, phenylglycine, thienylglycine, cyclohexylglycine, cyclohexylalanine, thienylalanine, naphthylalanine, octa-hydro-indole-2-carboxylic acid, adamantylalanine, benzothienylalanine, pyridylalanine, piperidylalanine, pyrazylalanine, quinolylalanine, thiazolylalanine, homocysteine, homophenylalanine, citrulline, homocitrulline, oxyproline (hydroxyproline),  $\alpha,\beta$ -diaminopropionic acid,  $\alpha,\gamma$ -diaminobutyric acid, aminomalonic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, cycloleucine, and 2-amino-4-pentenoic acid.

Examples of  $\beta$ -amino acid include  $\beta$ -alanine,  $\beta$ -aminobutyric acid, isoasparagine, 3-aminoadipic acid, 3-amino-phenylpropionic acid, 3-amino-2-hydroxy-4-phenyl aminobutyric acid, 3-amino-norbornane-carboxylic acid and 3-amino-bicycloheptane carboxylic acid.

Examples of  $\gamma$ -amino acid include  $\gamma$ -aminobutyric acid, isoglutamine, statin, 4-amino-3-hydroxy-5-cyclohexylpentanoic acid, 4-amino-3-hydroxy-5-phenylpentanoic acid,

6-aminopenicillanic acid and 3-aminoadamantine-1-carboxylic acid.

Examples of  $\epsilon$ -amino acid include  $\epsilon$ -amino caproic acid and 4-amino methyl-cyclohexane carboxylic acid.

5 Said natural amino acids include glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, cystine, methionine, aspartic acid, glutamic acid, lysine, arginine, phenylalanine, tyrosine, histidine, tryptophan, asparagine, glutamine, proline, ornithine and citrulline.

10 Said non-natural amino acids include norleucine,  $\gamma$ -methylleucine, tert-leucine, norvaline, homoarginine, homoserine, aminoisobutyric acid, aminoadipic acid (e.g.  $\alpha$ -aminoadipic acid), phenylglycine, thienylglycine, cyclohexylglycine, aminobutyric acid,  $\beta$ -alanine,  
 15 cyclohexylalanine, thienylalanine, naphthylalanine, adamantylalanine, benzothienylalanine, pyridylalanine, piperidylalanine, pyrazylalanine, quinolylalanine, thiazolylalanine, isoasparagine, isoglutamine, homocysteine, homophenylalanine, homocitrulline, oxyproline  
 20 (hydroxyproline), diaminopropionic acid, diaminobutyric acid, aminobenzoic acid, and N-methylated amino acids of natural and non-natural amino acids described above.

Substituents that may be substituted for side chains of these amino acid residues include (1)  $C_{1-6}$  alkyl group (e.g.  
 25 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and preferably  $C_{1-3}$  alkyl); (2) cyano group; (3) halogen (e.g. fluorine, chlorine, bromine, and iodine); (4) hydroxy- $C_{1-6}$  alkyl group (e.g. hydroxymethyl, and hydroxyethyl); (5)  $C_{1-6}$  alkoxy group (e.g. methoxy, ethoxy,  
 30 n-propoxy, isopropoxy, n-butoxy, tert-butoxy, and preferably  $C_{1-3}$  alkoxy); (6)  $C_{1-6}$  alkoxy-carbonyl group (e.g. methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, and preferably  $C_{1-3}$  alkoxy-carbonyl); (7)  $C_{1-4}$  acyl group (e.g. formyl such as formyl, acetyl, propionyl  
 35 and butyryl, and  $C_{2-4}$  alkanoyl); (8) hydroxy group; (9) groups represented by the formula:  $-S(O)a-R^{21}$  [where: a represents an

integer between 0 and 2; R<sup>21</sup> represents C<sub>1-6</sub> alkyl (specific examples are the same as the above)] such as methylthio, methanesulfinyl, methanesulfonyl, ethylthio, ethanesulfinyl, ethanesulfonyl; (10) benzyloxycarbonyl; (11) tosyl group; (12) carbamoyl group; (13) mercapto group; (14) amino group; (15) sulfo group; (16) phosphono group; (17) phospho group; (18) carboxyl group; (19) tetrazolyl group; (20) amino-C<sub>1-6</sub> alkyl group (e.g. amino methyl, amino ethyl); (21) amino allyl group; (22) thiazolyl group; (23) thienyl group; (24) oxazolyl group; (25) furyl group; (26) pyranlyl group; (27) pyridyl group; (28) pyrazyl group; (29) pyrazinyl group; (30) pyrimidinyl group; (31) pyridazinyl group; (32) indolyl group; (33) indodinyl group; (34) isoindolyl group; (35) pyrrolyl group; (36) imidazolyl group; (37) isothiazolyl group; (38) pyrazolyl group; (39) chromenyl group; (40) purinyl group; (41) quinolizinylyl group; (42) quinolyl group; (43) isoquinolyl group; (44) quinazolinyl group; (45) quinoxalinyl group; (46) cinnolinyl group; (47) morpholinyl group; (48) benzothienyl group; (49) benzofuranyl group; (50) benzimidazolyl; (51) benzimidazolyl group; (52) C<sub>3-8</sub> cycloalkyl group; (53) oxo group (54) C<sub>1-4</sub> alkyl group substituted by the substituents described in (2), (3), (5) to (19), and (22) to (52) above; (55) C<sub>1-4</sub> acyl group, such as formyl and C<sub>2-4</sub> alkanoyl, substituted by the substituents described in (2), (3), (5) to (19), and (22) to (52) above; (56) C<sub>6-10</sub> aryl group such as phenyl substituted by the substituents described in (1) to (52) above (e.g. mesityl, tolyl, xylyl, styrenyl); (57) C<sub>7-15</sub> aralkyl group such as benzyl substituted by the substituents described in (1) to (52) above (e.g. methylbenzyl methoxybenzyl); (58) C<sub>7-15</sub> aralkyl group (e.g. benzyl, phenethyl, benzhydryl, naphthylmethyl); and (59) C<sub>6-10</sub> aryl group (e.g. phenyl, naphthyl, indenyl).

Neutral substituents include (1) C<sub>1-6</sub> alkyl group (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and preferably C<sub>1-3</sub> alkyl); (2) cyano group; (3) halogen (e.g. fluorine, chlorine, bromine, and iodine); (4) hydroxy-C<sub>1-6</sub> alkyl group (e.g. hydroxymethyl, and



hydroxyethyl); (5) hydroxy group; (6) carbamoyl group; (7) mercapto group; (8) groups represented by the formula:

-S(O)a-R<sup>21</sup> (wherein the symbols have the same definitions as those given above), (9) C<sub>6-10</sub> aryl group (e.g. phenyl, naphthyl, indenyl, chromenyl); (10) thienyl group; (11) oxazolyl group; (12) furyl group; (13) indolyl group; (14) indodiny group; (15) isoindolyl group; (16) C<sub>3-8</sub> cycloalkyl group; (17) oxo group; (18) C<sub>1-6</sub> alkyl substituted by the substituents described in (2), (3), (5) to (16) above; (19) C<sub>6-10</sub> aryl group, such as phenyl and naphthyl, substituted by the substituents described in (1) to (16) above (e.g. mesityl, tolyl, xylyl, styrenyl); and (20) C<sub>7-15</sub> aralkyl group such as benzyl substituted by the substituents described in (1) to (16) above (e.g. methylbenzyl methoxybenzyl).

Acidic substituents include C<sub>1-4</sub> alkyl group, C<sub>6-10</sub> aryl group such as phenyl and naphthyl, C<sub>7-15</sub> aralkyl group such as benzyl, and carboxyl group that have been individually substituted by carboxyl group, sulfo group or tetrazolyl group.

Basic substituents include (1) amino-C<sub>1-6</sub> alkyl group (e.g. amino methyl, amino ethyl); (2) amino allyl group; (3) pyridyl group; (4) pyrazyl group; (5) pyrazinyl group; (6) pyridazinyl group; (7) imidazolyl group; (8) pyrazolyl group; (9) pyrazolyl group; (10) morpholinyl group; (11) amino group; (12) C<sub>1-4</sub> alkyl group substituted by the substituents described in (3) to (10) above; (13) C<sub>7-15</sub> aralkyl group such as benzyl substituted by the substituents described in (1) to (11) above; and (14) C<sub>6-10</sub> aryl group, such as phenyl and naphthyl, substituted by the substituents described in (1) to (11) above.

In this specification, acidic amino acids include, for example, amino acids with side chains having acid group such as carboxyl group, sulfo group; or tetrazolyl group. The specific examples of them specifically include glutamic acid, pyroglutamic acid, aspartic acid, cysteic acid, homocysteic acid, 3-(5-tetrazolyl)alanine, and

2-amino-4-(5-tetrazolyl)butyric acid.

In this specification, basic amino acids include, for

example, histidine, arginine, ornithine, lysine  
diaminopropionic acid, diaminobutyric acid and homoarginine.

Basic amino acids with substituted side chains  
specifically include N<sup>α</sup>-acetylarginine, N<sup>ε</sup>-tosylarginine,  
5 N<sup>ε</sup>-acetyllysine, N<sup>ε</sup>-methyllysine, and N<sup>ε</sup>-tosyllysine.

In this specification, neutral amino acids specifically  
include alanine, valine, norvaline, leucine, isoleucine,  
alloisoleucine, norleucine, tert-leucine, γ-methylleucine,  
proline, phenylglycine, phenylalanine, glutamine, asparagines,  
10 serine, threonine, glycine, cysteine, methionine, tryptophan,  
oxyproline (hydroxyproline) and cyclohexylalanine. Neutral  
amino acids with substituted side chains specifically include  
biphenylalanine.

In this specification, amino acid residues with aromatic  
15 side chains specifically include tryptophan, phenylalanine,  
tyrosine, 1-naphthylalanine, 2-naphthylalanine,  
2-thienylalanine, histidine, pyridylalanine  
(2-pyridylalanine), and O-methyltyrosine. Amino acid  
residues having aromatic side chains of which side chains are  
20 substituted specifically include 3-iodotyrosine,  
p-phosphonomethyl phenylalanine and O-phospho tyrosine.

In this specification, amino acid residues with side chains  
having hydroxy group include serine, threonine, tyrosine and  
oxyproline (hydroxyproline).

25 In this specification, the left end of a peptide or peptide  
chain indicates the N terminal (the amino terminal) and the  
right end the C terminal (the carboxyl terminal) following the  
conventional marking rules for peptides.

The C terminals of a peptide or peptide chain in the present  
30 invention is usually a carboxyl group (-COOH) or carboxylate  
(-COO<sup>-</sup>), but in some cases it can be an amide (-CONH<sub>2</sub>) or an  
ester (-COOR). R in an ester represents, for example, C<sub>1-6</sub> alkyl  
group including methyl, ethyl, n-propyl, isopropyl or n-butyl;  
C<sub>3-8</sub> cycloalkyl group including cyclopentyl and cyclohexyl; C<sub>6-12</sub>  
35 aryl group including phenyl and α-naphthyl; and C<sub>7-14</sub> aralkyl  
group including phenyl-C<sub>1-2</sub> alkyl such as benzyl, phenethyl and

benzhydryl, or  $\alpha$ -naphthyl- $C_{1-2}$  alkyl such as  $\alpha$ -naphthylmethyl, as well as pivaloyloxymethyl generally used as an ester for oral administration.

When peptides of the present invention have a carboxyl group or carboxylate other than the C terminal, those of which groups are amidated or esterified are also included among polypeptides of the present invention. For the ester, in this case, the ester at the C terminal described above may be used.

A peptide and peptide chain of the present invention include those that have an amino group in an amino acid residue at the N-terminal substituted by a substituent such as ①  $C_{2-6}$  alkanoyl group including formyl and acetyl,  $C_{1-8}$  acyl group including guanidinoacetyl, thienyl acrylyl and pyridyl acetyl; ②  $C_{1-6}$  alkyl group including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl; ③  $C_{6-10}$  aryl group including phenyl and naphthyl, or  $C_{7-16}$  aralkyl group including benzyl and phenethyl; ④ tosyl group (p-toluenesulfonyl group); ⑤ benzyloxycarbonyl group; ⑥ a group represented by the formula:  $-S(O)_a-R^{22}$  (where: a represents an integer between 0 and 2;  $R^{22}$  represents  $C_{1-6}$  alkyl (specific examples are the same as the above) such as methylthio, methanesulfinyl, methanesulfonyl, ethylthio, ethanesulfinyl, ethanesulfonyl; ⑦ t-butoxycarbonyl group; or ⑧ N-9-fluorenylmethoxycarbonyl), those with pyroglutaminated glutamine residue at the N-terminal, which is formed by being cleaved in vivo, those that have a substituent including -OH, -SH, amino group, imidazolyl group, indolyl group and guanidine group on a side chain of an amino acid in a molecule is protected by an appropriate protecting group such as  $C_{1-6}$  acyl group including  $C_{1-6}$  alkanoyl group such as formyl group and acetyl group), and conjugated proteins, including so-called glycoproteins that are formed by linking saccharide chains.

The formula above:

$X^1$ -Arg-Pro-Arg- $X^2$ -Ser-His-  $X^3$ -Gly-Pro- $X^4$ - $X^5$  wherein a side chain of each amino acid residue in -Arg-Pro-Arg-, -Ser-His-, and -Gly-Pro- may be substituted and substituents include those

described above.

In this specification,  $X^1$  represents "a hydrogen atom or an amino acid residue comprising 1 to 25 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain."

Substituent of said "1 to 25 amino acids each of which, whether identical or not, has a side chain which may be substituted" includes, for example, the one similar to "a substituent may be substituted for a side chain in an amino acid residue" described above.

Preferable examples where  $X^1$  represents "an amino acid residue having a side chain which may be substituted" include pyroglutamic acid which may be substituted, or glutamine having a side chain which may be substituted, and more preferably, pyroglutamic acid or glutamine.

Substituents for amino acid residues in said "an amino acid residue having a side chain which may be substituted," "pyroglutamic acid which may be substituted" and "glutamine having a side chain which may be substituted" include those similar to "a substituent which may be substituted by a side chain in an amino acid residue" above.

Preferred substituents for "pyroglutamic acid which may be substituted" include a benzyloxycarbonyl group.

Specific examples where  $X^1$  represents "a peptide chain comprising 2 to 25 amino acids each of which, whether identical or not, has a side chain which may be substituted" include a peptide represented by the formula:

$Y^1-Y^2$ , (wherein  $Y^1$  represents an amino acid residue comprising 1 to 17 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain, and  $Y^2$  represents an amino acid residue comprising 1 to 8 amino acids each of, whether identical or not, has a side chain which may be substituted, or a peptide chain.

Substituents for a side chain in an amino acid residue in an amino acid residue or a peptide chain represented by  $Y^1$  and  $Y^2$  described above include the one similar to "a substituent

which may be substituted by a side chain in an amino acid residue" described above.

Specific examples for  $Y^1$  described above include an amino acid residue or peptide chain represented by

- 5 (a) the formula  $A^1-A^2-A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein each of  $A^1$  to  $A^{17}$ , whether identical or not, represents an amino acid residue having a side chain which may be substituted),
- (b) the formula
- 10  $A^2-A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- (c) the formula  $A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- 15 (d) the formula  $A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- (e) the formula  $A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- 20 (f) the formula  $A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- (g) the formula  $A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- 25 (h) the formula  $A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- (i) the formula  $A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- (j) the formula  $A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- 30 (k) the formula  $A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$ , wherein the symbols have the same definitions as those given above),
- (l) the formula  $A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),
- 35 (m) the formula  $A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),

(n) the formula  $A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),

(o) the formula  $A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),

5 (p) the formula  $A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), or

(q)  $A^{17}$  (wherein  $A^{17}$  has the same definitions as that given above),

$A^1$  described above represents an amino acid residue having  
10 a side chain which may be substituted, preferably an amino acid residue having an aromatic side chain, more preferably an L-amino acid residue having an aromatic side chain, and further more preferably L-tyrosine.

Each of  $A^2$  and  $A^3$  described above, whether identical or not,  
15 represents an amino acid residue having a side chain which may be substituted, preferably a neutral amino acid residue having a side chain which may be substituted, more preferably a L-neutral amino acid residue having a side chain which may be substituted, and further more preferably L-leucine for  $A^2$  and  
20 L-valine for  $A^3$ .

$A^4$  described above represents an amino acid residue having a side chain which may be substituted, preferably a neutral or a basic amino acid residue having a side chain which may be substituted, more preferably a L-neutral or a L-basic amino acid  
25 residue having a side chain which may be substituted, and further more preferably L-lysine and N<sup>ε</sup>-acetyllysine.

$A^5$  described above represents an amino acid residue having a side chain which may be substituted, preferably a neutral amino acid residue having a side chain which may be substituted,  
30 more preferably L-proline which may be substituted, and further more preferably L-proline. Each of  $A^6$  and  $A^9$  described above, whether identical or not, represents an amino acid residue having a side chain which may be substituted, preferably a basic amino acid residue having a side chain which may be substituted,  
35 more preferably a L-basic amino acid residue having a side chain which may be substituted, and further more preferably

L-arginine.

A<sup>7</sup> and A<sup>10</sup> described above, whether identical or not, represents an amino acid residue having a side chain which may be substituted, and preferably an amino acid residue having a hydroxy group in a side chain thereof or a neutral amino acid residue having a side chain which may be substituted.

For A<sup>7</sup>, glycine which may be substituted, especially glycine, is preferably used.

A<sup>8</sup> described above represents an amino acid residue having a side chain which may be substituted, preferably an amino acid residue having L-proline or a hydroxy group in a side chain thereof, and more preferably L-serine, L-proline or oxyproline (hydroxyproline).

A<sup>10</sup> described above represents preferably an amino acid residue having a hydroxy group in a side chain thereof or a neutral amino acid residue having a side chain which may be substituted, and more preferably L-serine, L-threonine or L-asparagine.

A<sup>11</sup> through A<sup>14</sup> described above, whether identical or not, represent an amino acid residue having a side chain which may be substituted, preferably a neutral amino acid residue having a side chain which may be substituted, and more preferably glycine for A<sup>11</sup>, L-proline for A<sup>12</sup>, glycine for A<sup>13</sup>, and L-alanine and L-proline for A<sup>14</sup>.

A<sup>15</sup> described above represents an amino acid residue having a side chain which may be substituted, preferably an amino acid residue having an aromatic side chain, more preferably an L-amino acid residue having an aromatic side chain, and further more preferably L-tryptophan.

A<sup>16</sup> described above represents an amino acid residue having a side chain which may be substituted, preferably a neutral amino acid residue of which a side chain may be substituted, more preferably a neutral L-amino acid residue having a carbamoyl group, and further more preferably L-glutamine.

A neutral L-amino acid residue having a carbamoyl group includes L-glutamine and L-asparagine.

A<sup>17</sup> represents an amino acid residue having a side chain which may be substituted, preferably a neutral amino acid residue having a side chain which may be substituted, more preferably a neutral L-amino acid residue having carbamoyl group, and further more preferably glycine.

Specific examples for Y<sup>2</sup> described above include:

① the formula B<sup>1</sup>-B<sup>2</sup>-B<sup>3</sup>-B<sup>4</sup>-B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> where B<sup>1</sup> through B<sup>8</sup>, whether identical or not, represents an amino acid having a side chain which may be substituted,

② the formula B<sup>2</sup>-B<sup>3</sup>-B<sup>4</sup>-B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> (wherein the symbols have the same definitions as given above),

③ the formula B<sup>3</sup>-B<sup>4</sup>-B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> (wherein the symbols have the same definitions as given above),

④ the formula B<sup>4</sup>-B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> (wherein the symbols have the same definitions as given above),

⑤ the formula B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> (wherein the symbols have the same definitions as given above),

⑥ the formula B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> (wherein the symbols have the same definitions as given above),

⑦ the formula B<sup>7</sup>-B<sup>8</sup> wherein each symbol has the same definition as given above; or

⑧ the formula B<sup>8</sup> where B<sup>8</sup> has the same meaning as described above.

B<sup>1</sup> represents an amino acid residue having a side chain which may be substituted, preferably a neutral amino acid residue having a side chain which may be substituted, more preferably a neutral L-amino acid residue having a side chain which may be substituted, further more preferably glycine which may be substituted, and most preferably glycine.

B<sup>2</sup> through B<sup>4</sup>, whether identical or not, represent an amino acid residue having a side chain which may be substituted, preferably a basic amino acid residue having a side chain which may be substituted, more preferably a basic L-amino acid residue having a side chain which may be substituted, further more preferably L-arginine for B<sup>2</sup>, L-arginine for B<sup>3</sup>, L-lysine for B<sup>4</sup>.

B<sup>5</sup> described above represents an amino acid residue having



a side chain which may be substituted, preferably an amino acid residue having an aromatic side chain, more preferably an L-amino acid residue having an aromatic side chain, and further more preferably L-phenylalanine.

5 Each of B<sup>6</sup> and B<sup>7</sup> described above, whether identical or not, represents amino acid residues having a side chain which may be substituted, preferably a basic amino acid residue having a side chain which may be substituted, more preferably a basic L-amino acid residue having a side chain which may be substituted, and further more preferably L-arginine.

B<sup>8</sup> described above represents an amino acid residue having a side chain which may be substituted, preferably glutamine having a side chain which may be substituted, and more preferably L-glutamine.

15 Combinations of Y<sup>1</sup> and Y<sup>2</sup> include the cases that are represented by:

the formula expressed as (a) above + the formula expressed as ① above, that is the case where X<sup>1</sup> is represented by A<sup>1</sup>-A<sup>2</sup>-A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup>-B<sup>1</sup>-B<sup>2</sup>-B<sup>3</sup>-B<sup>4</sup>-B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup>: the explanation will be omitted in the subsequent combinations),

the formula expressed as (a) above + the formula expressed as ② above,

the formula expressed as (a) above + the formula expressed as ③ above,

the formula expressed as (a) above + the formula expressed as ④ above,

the formula expressed as (a) above + the formula expressed as ⑤ above,

the formula expressed as (a) above + the formula expressed as ⑥ above,

the formula expressed as (a) above + the formula expressed as ⑦ above,

the formula expressed as (a) above + the formula expressed as ⑧ above,

the formula expressed as (b) above + the formula expressed

the formula expressed as (d) above + the formula expressed

as ③ above,

the formula expressed as (d) above + the formula expressed

as ④ above,

the formula expressed as (d) above + the formula expressed

5 as ⑤ above,

the formula expressed as (d) above + the formula expressed

as ⑥ above,

the formula expressed as (d) above + the formula expressed

as ⑦ above,

10 the formula expressed as (d) above + the formula expressed

as ⑧ above,

the formula expressed as (e) above + the formula expressed

as ① above,

the formula expressed as (e) above + the formula expressed

15 as ② above,

the formula expressed as (e) above + the formula expressed

as ③ above,

the formula expressed as (e) above + the formula expressed

as ④ above,

20 the formula expressed as (e) above + the formula expressed

as ⑤ above,

the formula expressed as (e) above + the formula expressed

as ⑥ above,

the formula expressed as (e) above + the formula expressed

25 as ⑦ above,

the formula expressed as (e) above + the formula expressed

as ⑧ above,

the formula expressed as (f) above + the formula expressed

as ① above,

30 the formula expressed as (f) above + the formula expressed

as ② above,

the formula expressed as (f) above + the formula expressed

as ③ above,

the formula expressed as (f) above + the formula expressed

35 as ④ above,

the formula expressed as (f) above + the formula expressed

as ⑤ above,

the formula expressed as (f) above + the formula expressed

as ⑥ above,

the formula expressed as (f) above + the formula expressed

5 as ⑦ above,

the formula expressed as (f) above + the formula expressed

as ⑧ above,

the formula expressed as (g) above + the formula expressed

as ① above,

10 the formula expressed as (g) above + the formula expressed

as ② above,

the formula expressed as (g) above + the formula expressed

as ③ above,

the formula expressed as (g) above + the formula expressed

15 as ④ above,

the formula expressed as (g) above + the formula expressed

as ⑤ above,

the formula expressed as (g) above + the formula expressed

as ⑥ above,

20 the formula expressed as (g) above + the formula expressed

as ⑦ above,

the formula expressed as (g) above + the formula expressed

as ⑧ above,

the formula expressed as (h) above + the formula expressed

25 as ① above,

the formula expressed as (h) above + the formula expressed

as ② above,

the formula expressed as (h) above + the formula expressed

as ③ above,

30 the formula expressed as (h) above + the formula expressed

as ④ above,

the formula expressed as (h) above + the formula expressed

as ⑤ above,

the formula expressed as (h) above + the formula expressed

35 as ⑥ above,

the formula expressed as (h) above + the formula expressed

as ⑦ above,

the formula expressed as (h) above + the formula expressed

as ⑧ above,

the formula expressed as (i) above + the formula expressed

5 as ① above,

the formula expressed as (i) above + the formula expressed

as ② above,

the formula expressed as (i) above + the formula expressed

as ③ above,

10 the formula expressed as (i) above + the formula expressed

as ④ above,

the formula expressed as (i) above + the formula expressed

as ⑤ above,

the formula expressed as (i) above + the formula expressed

15 as ⑥ above,

the formula expressed as (i) above + the formula expressed

as ⑦ above,

the formula expressed as (i) above + the formula expressed

as ⑧ above,

20 the formula expressed as (j) above + the formula expressed

as ① above,

the formula expressed as (j) above + the formula expressed

as ② above,

the formula expressed as (j) above + the formula expressed

25 as ③ above,

the formula expressed as (j) above + the formula expressed

as ④ above,

the formula expressed as (j) above + the formula expressed

as ⑤ above,

30 the formula expressed as (j) above + the formula expressed

as ⑥ above,

the formula expressed as (j) above + the formula expressed

as ⑦ above,

the formula expressed as (j) above + the formula expressed

35 as ⑧ above,

the formula expressed as (k) above + the formula expressed

2025 RELEASE UNDER E.O. 14176

as ① above,

the formula expressed as (k) above + the formula expressed

as ② above,

the formula expressed as (k) above + the formula expressed

5 as ③ above,

the formula expressed as (k) above + the formula expressed

as ④ above,

the formula expressed as (k) above + the formula expressed

as ⑤ above,

10 the formula expressed as (k) above + the formula expressed

as ⑥ above,

the formula expressed as (k) above + the formula expressed

as ⑦ above,

the formula expressed as (k) above + the formula expressed

15 as ⑧ above,

the formula expressed as (l) above + the formula expressed

as ① above,

the formula expressed as (l) above + the formula expressed

as ② above,

20 the formula expressed as (l) above + the formula expressed

as ③ above,

the formula expressed as (l) above + the formula expressed

as ④ above,

the formula expressed as (l) above + the formula expressed

25 as ⑤ above,

the formula expressed as (l) above + the formula expressed

as ⑥ above,

the formula expressed as (l) above + the formula expressed

as ⑦ above,

30 the formula expressed as (l) above + the formula expressed

as ⑧ above,

the formula expressed as (m) above + the formula expressed

as ① above,

the formula expressed as (m) above + the formula expressed

35 as ② above,

the formula expressed as (m) above + the formula expressed

as ③ above,

the formula expressed as (m) above + the formula expressed

as ④ above,

the formula expressed as (m) above + the formula expressed

5 as ⑤ above,

the formula expressed as (m) above + the formula expressed

as ⑥ above,

the formula expressed as (m) above + the formula expressed

as ⑦ above,

10 the formula expressed as (m) above + the formula expressed

as ⑧ above,

the formula expressed as (n) above + the formula expressed

as ① above,

the formula expressed as (n) above + the formula expressed

15 as ② above,

the formula expressed as (n) above + the formula expressed

as ③ above,

the formula expressed as (n) above + the formula expressed

as ④ above,

20 the formula expressed as (n) above + the formula expressed

as ⑤ above,

the formula expressed as (n) above + the formula expressed

as ⑥ above,

the formula expressed as (n) above + the formula expressed

25 as ⑦ above,

the formula expressed as (n) above + the formula expressed

as ⑧ above,

the formula expressed as (o) above + the formula expressed

as ① above,

30 the formula expressed as (o) above + the formula expressed

as ② above,

the formula expressed as (o) above + the formula expressed

as ③ above,

the formula expressed as (o) above + the formula expressed

35 as ④ above,

the formula expressed as (o) above + the formula expressed

2025 RELEASE UNDER E.O. 14176

as ⑤ above,

the formula expressed as (o) above + the formula expressed  
as ⑥ above,

the formula expressed as (o) above + the formula expressed  
5 as ⑦ above,

the formula expressed as (o) above + the formula expressed  
as ⑧ above,

the formula expressed as (p) above + the formula expressed  
as ① above,

10 the formula expressed as (p) above + the formula expressed  
as ② above,

the formula expressed as (p) above + the formula expressed  
as ③ above,

15 the formula expressed as (p) above + the formula expressed  
as ④ above,

the formula expressed as (p) above + the formula expressed  
as ⑤ above,

the formula expressed as (p) above + the formula expressed  
as ⑥ above,

20 the formula expressed as (p) above + the formula expressed  
as ⑦ above,

the formula expressed as (p) above + the formula expressed  
as ⑧ above,

25 the formula expressed as (q) above + the formula expressed  
as ① above,

the formula expressed as (q) above + the formula expressed  
as ② above,

the formula expressed as (q) above + the formula expressed  
as ③ above,

30 the formula expressed as (q) above + the formula expressed  
as ④ above,

the formula expressed as (q) above + the formula expressed  
as ⑤ above,

the formula expressed as (q) above + the formula expressed  
35 as ⑥ above,

the formula expressed as (q) above + the formula expressed

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED  
DATE 08-14-2011 BY 60322 UCBAW



as ⑦ above, and

the formula expressed as (q) above + the formula expressed  
as ⑧ above, and in particular, preferably

the formula expressed as (a) above + the formula expressed

5 as ① above,

the formula expressed as (b) above + the formula expressed

as ① above,

the formula expressed as (c) above + the formula expressed

as ① above,

10 the formula expressed as (d) above + the formula expressed

as ① above,

the formula expressed as (e) above + the formula expressed

as ① above,

the formula expressed as (f) above + the formula expressed

15 as ① above,

the formula expressed as (g) above + the formula expressed

as ① above,

the formula expressed as (h) above + the formula expressed

as ① above,

20 the formula expressed as (i) above + the formula expressed

as ① above,

the formula expressed as (j) above + the formula expressed

as ① above,

the formula expressed as (k) above + the formula expressed

25 as ① above,

the formula expressed as (l) above + the formula expressed

as ① above,

the formula expressed as (m) above + the formula expressed

as ① above,

30 the formula expressed as (n) above + the formula expressed

as ① above,

the formula expressed as (o) above + the formula expressed

as ① above,

the formula expressed as (p) above + the formula expressed

35 as ① above, and

the formula expressed as (q) above + the formula expressed

as ① above.

More preferable examples, especially, include the cases that are represented by the formula expressed as (a) above + the formula expressed as ① above and the formula expressed as (b) above + the formula expressed as ① above.

Further more preferable examples for the cases that are represented by the formula expressed as (a) above + the formula expressed as ① above and the formula expressed as (b) above + the formula expressed as ① above are described as follows.

The case that is represented by the formula expressed as (b) above + the formula expressed as ① above refers to the case where  $X^1$  is represented by

$A^2-A^3-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-B^1-B^2-B^3-B^4-B^5-B^6-B^7-B^8$  where  $A^2$  to  $A^{17}$  and  $B^1$  to  $B^8$  have the same meanings as described above, for which preferable specific examples include where:

Each of  $A^2$  and  $A^3$ , whether identical or not, is an L-neutral amino acid residue having a side chain which may be substituted, and preferably L-leucine for  $A^2$  and L-valine for  $A^3$ ;

$A^4$  is an L-neutral or an L-basic amino acid residue having a side chain which may be substituted, and preferably L-glutamine, L-lysine or N<sup>a</sup>-acetyllysine;

$A^5$  is L-proline which may be substituted, and preferably L-proline;

Each of  $A^6$  and  $A^9$ , whether identical or not, is an L-basic amino acid residue having a side chain which may be substituted, and preferably L-arginine;

$A^7$  is glycine which may be substituted, and preferably glycine;

$A^8$  is an amino acid residue with a side chain having L-proline or a hydroxy group, and preferably L-serine, L-proline or oxyproline (hydroxyproline);

$A^{10}$  is preferably an amino acid residue with a side chain having a hydroxy group or a neutral amino acid residue having a side chain which may be substituted, and preferably L-serine,

L-threonine or L-asparagine;

A<sup>11</sup> is glycine, A<sup>12</sup> is L-proline, and A<sup>13</sup> is glycine, and A<sup>14</sup> is L-alanine or L-proline;

A<sup>15</sup> is an L-amino acid residue having aromatic side chains,  
5 and preferably L-tryptophan.

A<sup>16</sup> is a neutral L-amino acid residue having carbamoyl group, and preferably L-glutamine;

A<sup>17</sup> is a neutral L-amino acid residue, and preferably glycine;

10 B<sup>1</sup> is a neutral L-amino acid residue having a side chain which may be substituted, preferably glycine which may be substituted, and more preferably glycine;

B<sup>2</sup> through B<sup>4</sup>, whether identical or not, is a basic L-amino acid residue having a side chain which may be substituted, and  
15 preferably L-arginine for B<sup>2</sup>, L-arginine for B<sup>3</sup>, and L-lysine for B<sup>4</sup>;

B<sup>5</sup> is an L-amino acid residue having an aromatic side chain, and preferably L-phenylalanine;

Each of B<sup>6</sup> and B<sup>7</sup>, whether identical or not are basic L-amino  
20 acid residues of which the side chains may be substituted, and preferably L-arginine;

B<sup>8</sup> is glutamine which may be substituted, preferably L-glutamine.

The case that is represented by the formula expressed as  
25 (a) above + the formula expressed as ① above refers to the case where X<sup>1</sup> is represented by

A<sup>1</sup>-A<sup>2</sup>-A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup>-B<sup>1</sup>-B<sup>2</sup>-B<sup>3</sup>-  
B<sup>4</sup>-B<sup>5</sup>-B<sup>6</sup>-B<sup>7</sup>-B<sup>8</sup> where A<sup>1</sup> to A<sup>17</sup> and B<sup>1</sup> to B<sup>8</sup> have the same meanings  
as described above, for which preferable specific examples  
30 include where:

A<sup>1</sup> is an L-amino acid residue having aromatic side chains, and preferably L-tyrosine;

Each of A<sup>2</sup> and A<sup>3</sup>, whether identical or not, is an L-neutral amino acid residue having a side chain which may be substituted,  
35 and preferably L-leucine for A<sup>2</sup> and L-valine for A<sup>3</sup>;

A<sup>4</sup> is an L-neutral or an L-basic amino acid residue of which

a side chain is optionally substituted, and preferably L-glutamine, L- $\alpha$ -aminoadipic acid, L-lysine or N<sup>ε</sup>-acetyllysine;

5 A<sup>5</sup> is L-proline which may be substituted, and preferably L-proline;

Each of A<sup>6</sup> and A<sup>9</sup>, whether identical or not, is an L-basic amino acid residue having a side chains which may be substituted, and preferably L-arginine;

10 A<sup>7</sup> is glycine which may be substituted, and preferably glycine;

A<sup>8</sup> is an amino acid residue with a side chains having L-proline or a hydroxy group, and preferably L-serine, L-proline or oxyproline (hydroxyproline);

15 A<sup>10</sup> is preferably an amino acid residue with a side chain having a hydroxy group or a neutral amino acid residue of which a side chain is optionally substituted, and preferably L-serine, L-threonine or L-asparagine;

A<sup>11</sup> is glycine, A<sup>12</sup> is L-proline, and A<sup>13</sup> is glycine, and A<sup>14</sup> is L-alanine or L-proline;

20 A<sup>15</sup> is an L-amino acid residue having aromatic side chains, and preferably L-tryptophan.

A<sup>16</sup> is a neutral L-amino acid residue having carbamoyl group, and preferably L-glutamine;

25 A<sup>17</sup> is a neutral L-amino acid residue, and preferably glycine;

B<sup>1</sup> is a neutral L-amino acid residue of which a side chain is optionally substituted, preferably glycine which may be substituted, and more preferably glycine;

30 B<sup>2</sup> through B<sup>4</sup>, whether identical or not, is a basic L-amino acid residue having a side chain which may be substituted, and preferably L-arginine for B<sup>2</sup>, L-arginine for B<sup>3</sup>, and L-lysine for B<sup>4</sup>;

B<sup>5</sup> is an L-amino acid residue having aromatic side chains, and preferably L-phenylalanine;

35 Each of B<sup>6</sup> and B<sup>7</sup>, whether identical or not, is a basic L-amino acid residue a side chain which may be substituted, and

preferably L-arginine;

B<sup>8</sup> is glutamine which may be substituted, preferably L-glutamine.

Preferable specific examples for X<sup>1</sup> include:

5 (1) a hydrogen atom,

(2)

Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln  
-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln,

(3) pGlu,

10 (4)

Leu-Val-Adi(NH<sub>2</sub>)-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp  
p-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln,

(5)

Leu-Val-Lys(Ac)-Pro-Arg-Thr-Ser-Arg-Thr-Gly-Pro-Gly-Ala-Trp  
15 -Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln,

(6)

Tyr-Leu-Val-Lys-Pro-Arg-Thr-Ser-Arg-Thr-Gly-Pro-Gly-Ala-Trp  
-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln, and

(7) Z-pGlu.

20

In this specification, X<sup>2</sup> represents a neutral amino acid residue having a side chain which may be substituted, preferably L-leucine having a side chain which may be substituted, or L-norleucine having a side chain which may be substituted, and more preferably L-leucine or L-norleucine.

25

In this specification, X<sup>3</sup> represents a neutral amino acid residue having a side chain which may be substituted or a basic amino acid residue having a side chain which may be substituted. Substituents for a side chain of a basic amino acid residue include a C<sub>1-4</sub> acyl group, a tosyl group and a C<sub>1-6</sub> alkyl group.

30

A C<sub>1-4</sub> acyl group includes formyl including formyl, acetyl, propionyl and butyryl, and C<sub>2-4</sub> alkanoyl.

A C<sub>1-6</sub> alkyl group includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

35

X<sup>3</sup> preferably includes L-lysine having a side chain which may be substituted, L-norleucine having a side chain which may be substituted, and L-arginine having a side chain which may

be substituted; more preferably L-lysine, L-norleucine or L-arginine, each of which side chain which may be substituted by a C<sub>1-4</sub> acyl group that includes formyl including formyl, acetyl, propionyl and butyryl, and C<sub>2-4</sub> alkanoyl, a C<sub>1-6</sub> alkyl group that includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl, or a tosyl group; and further more preferably L-lysine, L-norleucine, L-arginine, N<sup>ε</sup>-acetyllysine, N<sup>ε</sup>-methylllysine, N<sup>ε</sup>-tosylllysine and N<sup>ε</sup>-tosyl arginine.

In this specification, X<sup>4</sup> represents a neutral or an aromatic amino acid residue having a bond or a side chain which may be substituted or a basic amino acid residue having a side chain which may be substituted. Preferably X<sup>4</sup> includes L-norleucine having a bond or a side chain which may be substituted, L-methionine having a side chain which may be substituted, L-methioninesulfoxide having a side chain which may be substituted, or L-alanine having a side chain which may be substituted, and more preferably a bond, L-norleucine or L-methionine, L-methioninesulfoxide, and L-cyclohexylalanine.

In this specification, X<sup>5</sup> represents ① an amino acid residue having a side chain which may be substituted or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ② a hydroxyl group or ③ a dipeptide chain comprising an amino acid residue having a side chain which may be substituted and an amino acid residue having a side chain which may be substituted, bound together, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group.

Preferably, X<sup>5</sup> represents ① a neutral amino acid residue having a side chain which may be substituted or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ② a hydroxyl group or ③ a dipeptide chain comprising a neutral amino acid residue having an aromatic side chain which may be substituted and an amino acid residue having a side chain which may be substituted,

bound together, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group.

More preferably,  $X^5$  represents ① L-proline having a side chain which may be substituted or an amino acid derivative having the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ② 4-chlorophenylalanine having a side chain which may be substituted or an amino acid derivative having the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ③ 2-naphthylalanine having a side chain which may be substituted or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ④ cyclohexylalanine having a side chain which may be substituted or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑤ a hydroxyl group, or ⑥ a dipeptide chain formed by binding together L-proline which may be substituted and (a) L-phenylalanine having a side chain which may be substituted, (b) L-tyrosine having a side chain which may be substituted, (c) L-2-thienylalanine having a side chain which may be substituted, (d) L-phenylglycine having a side chain which may be substituted or (e) L-2-pyridylalanine having a side chain which may be substituted, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group.

Further more preferably,  $X^5$  represents ① L-proline or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ② 4-chlorophenylalanine or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ③ 2-naphthylalanine or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ④ cyclohexylalanine or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑤ a hydroxyl group, or ⑥ a dipeptide chain formed by binding together L-proline and

L-phenylalanine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑦ a dipeptide chain formed by binding together L-proline and L-tyrosine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑧ a dipeptide chain formed by binding together L-proline and L-2-thienylalanine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑨ a dipeptide chain formed by binding together L-proline and L-phenylglycine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑩ a dipeptide chain formed by binding together L-proline and 4-chlorophenylalanine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑪ a dipeptide chain formed by binding together L-proline and 2-naphthylalanine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑫ a dipeptide chain formed by binding together L-proline and 3-iodotyrosine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑬ a dipeptide chain formed by binding together L-proline and O-methyltyrosine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ⑭ a dipeptide chain formed by binding together L-proline and L-2-pyridylalanine, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group.

Most preferably, "-X<sup>4</sup>-X<sup>5</sup>" includes:

- (1) -Nle-Pro-Phe,
- (2) -Nle-Pro-Tyr,
- (3) -Nle-Pro,
- (4) -Nle,
- (5) -Met-Pro-Phe,
- (6) -Nle-Pro-Thi,
- (7) -Nle-Pro-Phg,
- (8) -Nle-Pro-Pya(2),



- (9) -Met(O),  
 (10) -Met-Phe(Cl)  
 (11) -Met-Pro-Phe(Cl),  
 (12) -Met-Pro-Nal(2),  
 5 (13) -Met-Nal(2),  
 (14) -Met-Cha,  
 (15) -Cha-Pro-Phe,  
 (16) -Cha,  
 (17) -Met-Pro-Tyr(I), and  
 10 (18) -Met-Pro-Tyr(Me).

Specific examples for the peptides of the present invention include:

- (1)  
 Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln  
 15 -Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe,  
 (2)  
 Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln  
 -Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr,  
 20 (3) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe,  
 (4) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr,  
 (5) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro,  
 (6) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle,  
 25 (7) Ac-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr,  
 (8) Ac-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro,  
 (9) Ac-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle,  
 (10)  
 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Ac)-Gly-Pro-Met-Pro-Phe,  
 30 (11)  
 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Me)-Gly-Pro-Met-Pro-Phe,  
 (12)  
 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Ac)-Gly-Pro-Nle-Pro-Phe,  
 (13)  
 35 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Me)-Gly-Pro-Nle-Pro-Phe,  
 (14)

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Tos)-Gly-Pro-Nle-Pro-Phe,  
(15)

pGlu-Arg-Pro-Arg-Leu-Ser-His-Arg(Tos)-Gly-Pro-Nle-Pro-Phe,

(16) pGlu-Arg-Pro-Arg-Nle-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe,

5 (17) pGlu-Arg-Pro-Arg-Nle-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr,

(18) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Thi,

(19) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phg,

(20)

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Pya(2),

10 (21) Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr,

(22)

Leu-Val-Adi(NH<sub>2</sub>)-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Tr

p-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-S

er-His-Lys-Gly-Pro-Nle-Pro-Phe,

15 (23)

Leu-Val-Lys(Ac)-Pro-Arg-Thr-Ser-Arg-Thr-Gly-Pro-Gly-Ala-Trp

-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Se

r-His-Lys-Gly-Pro-Nle-Pro-Tyr,

(24)

20 Tyr-Leu-Val-Lys-Pro-Arg-Thr-Ser-Arg-Thr-Gly-Pro-Gly-Ala-Trp

-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Se

r-His-Lys-Gly-Pro-Nle-Pro-Phe,

(25)

Z-pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Ac)-Gly-Pro-Nle-Pro-Phe,

25 (26)

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met(O),

(27)

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr

,

30 (28) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Phe(Cl),

(29)

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe(Cl),

(30) Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Nal(2),

(31) Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Nal(2),

35 (32) Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe(Cl),

(33) Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Phe(Cl),

(34) Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Cha,

(35) pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Cha-Pro-Phe,

(36) Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Cha,

(37)

5 Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe  
(Cl),

(38)

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Nle-Gly-Pro-Met-Pro-Phe  
(Cl),

10 (39)

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Nle-Gly-Pro-Met-Pro-Tyr  
(I),

(40)

15 Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Nle-Gly-Pro-Met-Pro-Tyr  
(Me)

Salts of the peptides of the present invention, may be those formed with physiologically acceptable bases such as alkaline metals, or acids (organic or inorganic acids), physiologically acceptable acid addition salts are especially preferable.

20 These salts include salts with inorganic acids (e.g. hydrochloric acid, phosphoric acid, hydrobromic acid, and sulfuric acid), or salts with organic acids (e.g. acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid and benzenesulfonic acid).

25 Peptides of the present invention can be produced by modifying them following the peptide synthesis method described later after obtaining natural ligands from tissues or cells of humans or other warm-blooded animals through a peptide refining process. Alternatively, these peptides can also be produced not with the natural ligand as a raw material but by following the peptide synthesis method described later.

30 In the case where natural ligands are produced from tissues or cells of humans or other warm-blooded animals, they can be refined and isolated by first homogenizing the aforementioned

tissues or cells, extracting with acids, and then by processing the resultant extracts using a combination of chromatographies such as salting-out, dialysis, gel-filtration, reverse phase chromatography, ion exchange chromatography, and affinity chromatography.

Natural ligands can be obtained, for example, in accordance with the processes described in WO 99/33976 (Japanese Patent Application No. 220853-1998).

Peptides of the present invention can be produced through known processes for peptide synthesis. For example, both solid and liquid phase synthesis methods may be used for peptide synthesis. The targeted peptide can be produced by condensing a partial peptide or an amino acid that may form the peptide of the present invention and the residual parts, and then by eliminating the protecting group if the product possesses one. Known methods of condensation or elimination of protecting groups are listed below:

1. M. Bodanszky and M.A. Ondetti, *Peptide Synthesis*, Interscience Publishers, New York, 1966.
2. Schoroeder and Luebke, *The Peptide*, Academic Press, New York, 1965.
3. Nobuo Izumiya et al., *Fundamental and Experiments of Peptide Synthesis*, MARUZEN CO., LTD., 1975.
4. Haruaki Yajima and Shunpei Sakakibara, *Lecture Series of the Biochemical Experiments 1, Chemistry of Proteins IV*, 205, 1977
5. Haruaki Yajima (Edited), *Development of Pharmaceutical Products (Sequel) Vol. 14, Peptide Synthesis*, Hirokawa Shoten

After this reaction, a combination of conventional purification processes, such as solvent extraction, distillation, column chromatography, liquid chromatography or re-crystallization, can be used to refine and isolate peptides of the present invention. If the peptide obtained through the aforementioned process is a free radical, it can be transformed into appropriate salts through known processes, and if it is a salt, it can be transformed into a free radical by a known process.

To condense protected amino acids or peptides, various activating reagents for peptide synthesis can be used, but trisphosponiums, tetramethyluroniums, and carbodimides are especially suitable. Trisphosponiums include

5 benzotriazol-1-yl-oxytris(pyrrolydino)phosponium  
hexafluorophosphate (PyBOP), and  
bromotris(pyrrolydino)phosponium  
hexafluorophosphate(PyBroP). Tetramethyluroniums include  
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafl  
10 uoroborate,  
2-(5-norbornene-2,3-dicarboximido)-1,1,3,3-tetramethyluroni  
um tetrafluoroborate, and  
O-(N-succinimidyl)-1,1,3,3-tetramethyluronium  
terafluoroborate.

15 Carbodimides include DCC, N,N'-diisopropylcarbodiimide,  
and N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide.  
Addition of racemization inhibitors, such as HONB, HOBt, or  
HOObt, is preferable for such condensation processes.  
Solvents used for condensation are selected from those known  
20 to be used in peptide condensation reactions.

For example, acid amides such as anhydrous or hydrous N,  
N-dimethylformamide, N, N-dimethylacetamide and  
N-methylpyrrolidone, halogenated hydrocarbons such as  
methylene chloride and chloroform, alcohols such as  
25 trifluoroethanol, sulfoxides such as dimethyl sulfoxide,  
tertiary amine such as pyridine, ethers such as dioxane and  
tetrahydrofuran, nitriles such as acetonitrile and  
propionitrile, esters such as ethyl acetate and methyl acetate,  
or appropriate mixture of these are used.

30 The reaction temperature may be selected from a known range  
for peptide bonding reactions, and is normally between -20°C  
and 50°C. Activated amino acid derivatives are normally used  
in excess quantities of 1.5 to 4 times. In solid phase synthesis,  
sufficient condensation can be obtained by repeating  
35 condensation reactions without eliminating the protecting  
groups if condensation is shown to be incomplete as a result

of ninhydrin reaction-based tests. If satisfactory condensation cannot be obtained through the repetition of reactions, unreacted amino acids can be acetylated with acetic anhydrides or acetylmidazole, so that later reactions will not be affected.

Protecting groups for an amino group of a raw material amino acid include Z, Boc, tert-pentyloxycarbonyl, isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl, Cl-Z, Br-Z, adamantyloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulfenyl, diphenylphosphinothioyl and Fmoc. Protecting groups for a carboxyl group include, for example, C<sub>1-6</sub> alkyl group, C<sub>3-8</sub> cycloalkyl group, C<sub>7-14</sub> aralkyl described above as R, as well as, allyl, 2-adamantyl, 4-nitrobenzyl, 4-methoxybenzyl, 4-chlorobenzyl, phenacyl group, benzyloxycarbonylhydrazide, tertiary butoxycarbonylhydrazide and tritylhydrazide.

Hydroxyl groups of serine and threonine may be protected by esterification or etherification, for instance. Groups suitable for such esterification include lower (C<sub>2-4</sub>) alkanoyl groups such as an acetyl group and a group introduced from organic acids including aroyl groups such as benzoyl group. Groups suitable for such etherification include a benzyl group, a tetra-hydropyranyl group, a tertiary-butyl group and a trityl group (Trt).

Protecting groups for a phenolic hydroxyl group of tyrosine include Bzl, 2,6-dichlorobenzyl, 2-nitrobenzyl, Br-Z and tertiary-butyl.

Protecting groups for imidazolyl of histidine include Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), DNP, Bom, Bum, Boc, Trt and Fmoc.

Protecting groups for a guanidino group of arginine include Tos, Z, 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), p-methoxybenzene sulfonyl (MBS), 2,2,5,7,8-Pentamethyl chroman-6-sulfonyl (Pmc), mesitylene-2-sulfonyl (Mts), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), Boc, Z and NO<sub>2</sub>.

Protecting groups for a side chain amino group of lysine include Z, Cl-Z, trifluoroacetyl, Boc, Fmoc, Trt, Mtr and 4,4-dimethyl-2,6-dioxo cyclohexylideneyl (Dde).

Indolyl protecting groups for tryptophan include formyl (For), Z, Boc, Mts and Mtr.

Protecting groups for asparagine and glutamine include Trt, xanthyl (Xan), 4,4'-dimethoxy benzhydryl (Mbh) and 2,4,6-trimethoxybenzyl (Tmob).

Activated carboxyl groups of raw materials include, for example, corresponding acid anhydrides, azide, activated esters [alcohols (for example, ester with pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, paranitrophenol, HONB, N-hydroxysuximide, and 1-hydroxybenzotriazole (HOBt))]. Activated amino groups of raw materials include, for example, corresponding phosphorous-amide.

Elimination of protecting groups can be achieved by procedures including catalytic reduction in flowing hydrogen in the presence of catalyst such as palladium black and palladium on carbon; acid treatment with anhydrous hydrogen fluoride, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, bromotrimethylsilane/trimethylsilyl bromide (TMSBr), trimethylsilyl trifluoromethanesulfonate, tetrafluoroboric acid, tris(trifluoro)boron, boron tribromide, or mixture of the above; base treatment with diisopropylethylamine, triethylamine, piperidine, or piperazine; and reduction by using sodium in liquid ammonia.

While the elimination reaction in the acid treatment is usually performed at a temperature range of -20 to 40°C, addition of cation scavengers such as anisole, phenol, thioanisole, metacresol, and paracresol; and of dimethylsulfide, 1,4-butanedithiol, or 1,2-ethanedithiol are useful. 2,4-dinitrophenyl group used as an imidazolyl protecting group for histidine can be eliminated by treatment with thiophenol, and a formyl group used as an indole protecting group for tryptophan can be eliminated by base treatment with dilute

sodium hydroxide or dilute ammonia, other than the deprotection with acid treatment in the presence of 1,2-ethanedithiol or 1,4-butanedithiol.

Protection of the function group that should not be involved in reactions of raw materials and the protecting group, as well as elimination of the protecting group and activation of the function group involved in the reaction can be appropriately selected from known groups or known procedures.

The peptide amide can be obtained by solid phase synthesis using resins for synthesizing amide forms or amidating  $\alpha$ -carboxyl group of an amino acid at the carboxyl terminal, elongating the peptide chain towards the amino group side for a desired length, producing a peptide deprived of only the protecting group of an  $\alpha$ -amino group at the N terminal of said peptide chain and a peptide (or amino acid) deprived of only the protecting group of carboxyl group at the N terminal of said peptide chains and by condensing both peptides in a mixed solvent above. The details of the condensation reaction are the same as the above. After the protected peptide obtained by condensation is purified, all protecting groups are eliminated to obtain desired crude polypeptides. These crude peptides may be purified by deploying any of the various known procedures of purification and major fractions are lyophilized to obtain desired peptide amide.

To obtain the peptide ester, after condensing the  $\alpha$ -carboxyl group of an amino acid at the carboxyl terminal with desired alcohols to obtain amino acid ester, desired peptide ester can be obtained in a similar way to that for the peptide amide.

The peptides of the present invention may be fusion proteins that are bound together with proteins of well-known functions or properties.

The peptides of the present invention may be used for ① research for physiological activities of the peptides of the present invention, ② development of receptor binding assay system using the expression system of recombinant receptor



proteins and screening of candidate compounds for potent pharmaceutical products and ③ development of pharmaceuticals such as a central nervous function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive function regulator, a metabolic function regulator or a reproductive organ function regulator.

In particular, since screening of specific G protein-coupled receptor protein agonists or antagonists of warm-blooded animals including humans can be performed by the receptor binding assay system using the expression system of recombinant G protein-coupled receptor proteins described later, said agonists or antagonists can be used as prophylactic or therapeutic drugs.

Furthermore, regarding ③ above, the peptides of the present invention are useful as a safe medicine with low toxicity since these peptides are identified as ligands by G protein-coupled receptor proteins expressed in the central nervous system, the circulatory system, the heart, immune system, digestive system, metabolic system, or the reproductive system. Since the peptides of the present invention are involved in activities of central nervous functions, circulatory functions, cardiac functions, immune functions, digestive functions, metabolic functions, or reproductive organ functions, they can be used as therapeutic or prophylactic drugs against disorders, such as: dementia including dementia associated with senile dementia, cerebrovascular dementia, dementia associated with retroplastic diseases of the systemic degeneration type (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's disease), dementia associated with infective diseases (e.g. slow virus infections such as Creutzfeldt-Jakob disease), dementia associated with endocrine disease, metabolic disease or toxic disease (e.g. hypothyroidism, vitamin B12 deficiency disease, alcoholism, and intoxication with various drugs, metal or organic compound), dementia associated with neoplastic diseases such (e.g. brain tumor), and dementia associated with traumatopathy (e.g. chronic

subdural hematoma); depression, Attention deficit hyperactivity disorder(minimal brain dysfunction) syndrome; disturbance of consciousness; anxiety disorder; schizophrenia; phobia, growth hormone secretion disorder (e.g. gigantism, acromegaly), hyperphagia, polyphagia, hypercholesterolemia, hyperglyceridemia, hyperlipidemia, hyperprolactinemia, diabetes (e.g. diabetic complication, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy); cancer (e.g. breast cancer, lymphatic leukemia, lung cancer, bladder cancer, ovarian cancer and prostate cancer); pancreatitis, renal diseases (e.g. chronic renal failure, nephritis); Turner's syndrome; neuropathy; rheumatoid arthritis; spinal cord injury; transient ischemic attack; amyotrophic lateral sclerosis; acute myocardial infarct; spinocerebellar degeneration; fracture; injury; atopic dermatitis; osteoporosis; asthma; epilepsy; infertility; arteriosclerosis; emphysema pulmonum; pulmonary edema or hypogalactia. Also they can be applied as an agent that improves the nutritional state and a vasopressor that are used post-operatively..

In addition, the peptides of the present invention can be used as therapeutic or prophylactic drugs against AIDS (Acquired Immune Deficiency Syndrome) or the like.

When the peptides of the present invention are used as the pharmaceuticals described above, they can be used following conventional methods. For example, they may be given orally as tablets sugar-coated or enteric coated as necessary, capsules, elixirs or microcapsules, or may be given parenterally in the form of injections such as aseptic solution with water or other pharmaceutically acceptable liquid, or suspensions. For example, they may be manufactured by mixing said compounds or their salts with physiologically acceptable carriers, flavors, excipients, vehicles, preservatives, stabilizers and binders with a unit dose form required in commonly accepted manufacturing practices. The content of the active ingredient in these preparations should be determined

based on the appropriate dose within the indicated range.

Additives that may be mixed into tablets or capsules include, for example, binders such as gelatin, corn starch, gum traganth and gum Arabic, excipients such as crystalline cellulose, fillers such as corn starch, gelatin, alginic acid, lubricants such as magnesium stearate, sweetening agent such as cane sugar, lactose and saccharin, and flavors such as peppermint, Gaultheria ovatifolia essence and cherry. When the preparation unit form is a capsule, liquid carriers such as oils may be contained in addition to the above-mentioned types of materials. Aseptic compositions for injections can be prepared following a usual manufacturing practice where active substances, or naturally occurring vegetable oils such as sesame oil and coconut oil in vehicles such as water for injections are dissolved or suspended.

Aqueous solutions for injection include, for example, physiologic saline, isotonic solutions containing glucose and other adjuvant (e.g. D-sorbitol, D-mannitol, sodium chloride) and may be used in combination with appropriate solubilizers including alcohol (e.g. ethanol), polyalcohol (e.g. polypropylene glycol and polyethylene glycol), nonionic surfactant (e.g. Polysorbate 80<sup>TM</sup> and HCO-50). Oily liquids include sesame oil and soybean oil, and may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizer.

They may be used in combination with buffers (e.g. phosphate buffer and sodium acetate), soothing agents (e.g. benzalkonium chloride and procaine hydrochloride), stabilizers (e.g. human serum albumin and polyethylene glycol), preservatives (e.g. benzyl alcohol and phenol) and antioxidants. Preparations for injection are usually filled into appropriate ampules. Pharmaceuticals produced in such ways can be administered, for example, to human or mammals (e.g. mice, rats, guinea pigs, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, hamadryas baboon and chimpanzees), because of their safety and low toxicity.

The dose of the peptides of the present invention for oral administration is generally approximately 0.1 to 100 mg/day, preferably approximately 1.0 to 50 mg/day, or more preferably approximately 1.0 to 20 m/day for adult patients of 60 kg, varying although depending on symptoms. For parenteral administration, although the dose varies depending on subjects, target organs, symptoms, or administration methods, for example, it is advantageous in the form of injections that they are administered intravenously at doses of approximately 0.01 to 30 mg/day, preferably approximately 0.1 to 20 mg/day, and more preferably approximately 0.1 to 10 mg/day for adult patients with emphysema pulmonum with a body weight of 60 kg. For other animals, they can be administered at doses that are equivalent to those values with 60 kg.

G protein-coupled receptor proteins corresponding to the above-mentioned peptides of the present invention are G protein-coupled receptor proteins derived from any tissues (e.g. hypophysis, pancreas, brain, kidney, liver, genital gland, thyroid, gallbladder, bone marrow, adrenal, skin, muscle, lung, gastrointestinal tract, blood vessel, and heart) or cells of human or mammals such as mammalian warm-blooded animals (e.g. rabbits, sheep, goats, rats, mice, guinea pigs, cattle, horses, and pigs) and birds (e.g. chickens, doves, ducks, geese, quails), and may be anything if it contains the same or practically the same amino acid sequence as the amino acid sequence represented by the Sequence ID No.:26. In other words, G protein-coupled receptor proteins contain, in addition to proteins containing the amino acid sequence represented by the Sequence ID No.:26 in this specification, proteins that contain the amino acid sequences having approximately 90 to 99.9% homology with the amino acid sequence represented by the Sequence ID No.:26 in this specification, and include a protein with practically equivalent activities as those that contain the amino acid sequence represented by the Sequence ID No.:26 in this specification.

Activities shown by these proteins include, for example,

ligand binding activities and signal transduction activities. "Practically equivalent" means that ligand binding activities are qualitatively equal. Therefore, quantitative factors such as the strength of ligand binding activities or factors such as molecular weights of receptor proteins may be different.

Additionally, G protein-coupled receptor proteins include those of which Met at the N terminal is protected by protecting groups (e.g. C<sub>1-6</sub> acyl group including C<sub>2-6</sub> alkanoyl group such as formyl and acetyl), those of which the N terminal side of Gln is cleaved in vivo and said Gln pyroglutamated, those of which a side chain of an amino acid residue in the molecule is protected by appropriate protecting groups (e.g. C<sub>1-6</sub> acyl group such as formyl group and acetyl group), and conjugated proteins that include so-called glycoproteins formed by linking saccharide chains.

Salts of G protein-coupled receptor proteins include those that are similar to salts of the peptides described above.

G protein-coupled receptor proteins, their salts or partial peptides can be produced from tissues or cells of human or warm-blooded animals by using known purification methods of proteins, or following known peptide synthesis methods described above.

For partial peptides of G protein-coupled receptor proteins, for example, a site exposed to the outside of the cell membrane among molecules of G protein-coupled receptor proteins may be used. In other words, they are peptides containing the portion that has been analyzed to be an extracellular region (hydrophilic site) by the hydrophobic plot analysis of G protein-coupled receptor proteins. Similarly, peptides containing a hydrophobic site may also be used. Peptides that contain each domain individually or partial peptides that contain multiple domains at the same time may also be used.

As for the salts of partial peptides of G protein-coupled receptor proteins, those similar to salts of the peptides described above are used.

DNAs that code G protein-coupled receptor proteins may be

any of those that contain the base sequence that codes G protein-coupled receptor proteins containing the same or practically the same amino acid sequence as the amino acid sequence of the Sequence ID No.:26 in this specification. They may also be either of genomic DNAs, genomic DNA library, cDNAs derived from tissues or cells, cDNA library derived from tissues or cells, or synthesized DNAs. Vectors used for a library may be bacteriophage, plasmid, cosmid, or phagemid. They may be amplified directly by known RT-PCR methods using the part prepared from RNA fractions of tissues or cells.

More specifically, as DNAs that code G protein-coupled receptor proteins containing the amino acid sequence represented by the Sequence ID No.:26 in this specification, DNA containing the base sequence represented by the Sequence ID No.:27 in this specification is used.

Here, the use of the peptides or their salts in the present invention (hereinafter may be abbreviated as the peptides or the like of the present invention) is specifically described as follows:

(1) Prophylactic or therapeutic drugs for ligand peptide deficiency

The peptides or the like of the present invention can be used as prophylactic or therapeutic drugs for deficiency of ligand peptide or G protein-coupled receptor protein (APJ) according to activities that the peptides or the like of the present invention have against G protein-coupled receptor proteins (APJ).

For example, if a patient could be not expected to have the physiological activity of ligands, such as activities of regulating central nervous functions, circulatory functions, cardiac functions, immune functions, digestive functions, metabolic functions, and reproductive organ functions, due to decreased G protein-coupled receptor protein (APJ) in vivo, the ligand peptide activity can be made sufficiently effective by administering the peptides or the like of the present invention to said patient to increase the amount of in vivo ligand peptide

of said patient. Thus the peptides or the like of the present invention can be used as safe and low toxic prophylactic or therapeutic drugs for ligand peptide deficiency.

(2) Quantitative assay on G protein-coupled receptor protein (APJ) for ligand peptide

Since the peptides or the like of the present invention have binding capacities for G protein-coupled receptor proteins (APJ) or their salts and partial peptides of said receptor proteins or their salts, in vivo concentrations of G protein-coupled receptor proteins (APJ) or their salts, or partial peptides of said receptor proteins, their amides, esters, or salts thereof can be determined with a high sensitivity.

For partial peptides of said G protein-coupled receptor proteins (APJ), for example, a site that is exposed to the outside of the cell membrane among molecules of G protein-coupled receptor proteins may be used. In other words, they are peptides containing the portion that has been analyzed to be an extracellular region (hydrophilic site) by the hydrophobic plot analysis of G protein-coupled receptor proteins. Similarly, peptides containing a hydrophobic site as a part may also be used. Peptides that contain each domain individually or partial peptides that contain multiple domains at the same time may also be used.

Amides and esters of partial peptides of G protein-coupled receptor proteins (APJ) can be obtained in the same way as the amides and esters of the peptides of the present invention. Salts similar to the salts of the peptides of the present invention can be used as salts of partial peptides of G protein-coupled receptor proteins (APJ).

This quantitative assay can be applied in combination with the competitive assay, for example.

In other words, concentrations of G protein-coupled receptor proteins (APJ) or their salts, or partial peptides of G protein-coupled receptor proteins (APJ), their amides, esters, or salts thereof in the specimen can be determined by bringing

it into contact with the peptides or the like of the present invention. More specifically, it can be applied in accordance with known procedures such as ① and ② described below or one similar to them.

- 5 ① Hiroshi Irie, editor, Radioimmunoassay, Kodansha, 1974  
 ② Hiroshi Irie, editor, Radioimmunoassay (Sequel), Kodansha, 1979

(3) Screening procedures for compounds that may alter the binding capacities of G protein-coupled receptor proteins (APJ) and the peptides or the like of the present invention

10 Compounds (e.g. peptides, proteins, non-peptide compounds, synthesized compounds and fermentation products) or their salts, which may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ) can be screened by using G protein-coupled receptor proteins (APJ) or their salts, or said partial peptides, their amides, esters, or salts thereof, or by establishing an expression system of recombinant receptor proteins (APJ) and using the receptor binding assay system with said expression system. These compounds include compounds having cell stimulation activities through G protein-coupled receptors (APJ) (e.g. activities that promote or inhibit arachidonic acid liberation, acetylcholine liberation, intracellular  $Ca^{2+}$  liberation, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, the variation in membrane potential, intracellular protein phosphorylation, and c-fos activation or pH decrease) (G protein-coupled receptor agonists) and compounds not containing said cell stimulating activities (G protein-coupled receptor antagonists). "To alter binding capacities" implies both inhibiting binding with the peptides or the like in the present invention and promoting binding with the same.

Namely, the present invention provides screening procedures for compounds or their salts that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ)



described above, which are characterized by making a comparison between (i) the case where the peptides or the like of the present invention are brought into contact with G protein-coupled receptor proteins (APJ) or their salts, or partial peptides of said receptor proteins or their salts and (ii) the case where the peptides or the like of the present invention and test compounds are brought into contact with G protein-coupled receptor proteins (APJ) described above or their salts, or partial peptides of said receptor proteins, their amides, esters, or salts thereof.

In the screening procedures of the present invention, the binding or cell stimulating activities of the peptides or the like of the present invention relative to said G protein-coupled receptor proteins (APJ) or partial peptides of said receptor proteins in (i) the case where the peptides or the like of the present invention are brought into contact with G protein-coupled receptor proteins (APJ) described above, or partial peptides of said receptor proteins and (ii) the case where the peptides or the like of the present invention and test compounds are brought into contact with G protein-coupled receptor proteins (APJ) described above, or partial peptides of said receptor proteins are determined and compared them.

The screening procedures of the present invention specifically include:

- ① Screening procedures for compounds or their salts that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ), which are characterized by determining the binding of the labeled peptides or the like of the present invention relative to said G protein-coupled receptor proteins (APJ) or said partial peptides, their amides, esters or salts thereof in the case where the labeled peptides or the like of the present invention are brought into contact with G protein-coupled receptor proteins (APJ) described above or their salts, or partial peptides of G protein-coupled receptor proteins (APJ), their amides, esters, or salts thereof, and the case where the

labeled peptides or the like of the present invention and test compounds are brought into contact with G protein-coupled receptor proteins (APJ) or their salts, or partial peptides of G protein-coupled receptor proteins (APJ), their amides, esters, or salts thereof, and comparing them.

② Screening procedures for compounds or their salts that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ), which are characterized by determining the binding of the labeled peptides or the like of the present invention relative to the cells or the membrane fractions of the cells in the case where the labeled peptides or the like of the present invention are brought into contact with cells that contain G protein-coupled receptor proteins (APJ) or membrane fractions of said cells, and the case where the labeled peptides or the like of the present invention and test compounds are brought into contact with cells that contain G protein-coupled receptor proteins (APJ) or membrane fractions of said cells, and comparing them.

③ Screening procedures for compounds or their salts that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ), which are characterized by determining the binding of the labeled peptides or the like of the present invention relative to said G protein-coupled receptor proteins in the case where the labeled peptides or the like of the present invention are brought into contact with G protein-coupled receptor proteins (APJ) expressed on the cell membrane by culturing transformants containing DNAs that code G protein-coupled receptor proteins (APJ), and the case where the labeled peptides or the like of the present invention and test compounds are brought into contact with G protein-coupled receptor proteins (APJ) expressed on the cell membrane by culturing transformants containing DNAs that code G protein-coupled receptor proteins (APJ), and comparing them.

④ Screening procedures for compounds or their salts that may

alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ), which are characterized by determining cell stimulation activities through G protein-coupled receptors (APJ) (e.g. activities that promote or inhibit arachidonic acid liberation, acetylcholine liberation, intracellular  $\text{Ca}^{2+}$  liberation, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, the variation in membrane potential, intracellular protein phosphorylation, c-fos activation or pH decrease) in the case where compounds that activate G protein-coupled receptor (APJ) (e.g. the peptides of the present invention) are brought into contact with cells containing G protein-coupled receptor proteins (APJ), and the case where compounds that activate G protein-coupled receptor (APJ) and test compounds are brought into contact with cells containing G protein-coupled receptor proteins (APJ), and comparing them.

⑤ Screening procedures for compounds or their salts that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ), which are characterized by determining cell stimulation activities through G protein-coupled receptors (APJ) (e.g. activities that promote or inhibit arachidonic acid liberation, acetylcholine liberation, intracellular  $\text{Ca}^{2+}$  liberation, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, the variation in membrane potential, intracellular protein phosphorylation, c-fos activation or pH decrease) in the case where compounds that activate G protein-coupled receptor (APJ) (e.g. the peptides of the present invention) are brought into contact with G protein-coupled receptor proteins (APJ) expressed on the cell membrane by culturing transformants containing DNAs that code G protein-coupled receptor proteins (APJ), and the case where compounds that activate G protein-coupled receptor (APJ) and test compounds are brought into contact with G protein-coupled receptor proteins (APJ) expressed on the cell membrane by

culturing transformants containing DNAs that code G protein-coupled receptor proteins (APJ), and comparing them.

Here, the screening procedures of the present invention is specifically described as follows:

5 First, G protein-coupled receptor proteins (APJ) that are used for the screening procedures of the present invention may be any of those that contain G protein-coupled receptor proteins described above or partial peptides of G protein-coupled receptor proteins, preferably membrane fractions of human or  
10 warm-blooded animal organs. However, since the availability of human-derived organs especially is extremely limited, G protein-coupled receptor proteins (APJ) that are massively expressed by using recombinants are suitable for screening.

Preparation methods described later may be followed when  
15 cells or fractions of said cell membranes that contain G protein-coupled receptor proteins are used for the screening procedures of the present invention.

When cells that contain G protein-coupled receptor proteins are used, said cells may be fixated with glutaraldehyde or formalin. Fixation methods may be carried out following any  
20 known method.

A cell that contains G protein-coupled receptor proteins refers to a host cell expressing G protein-coupled receptor proteins. *Esherichia*, *Bacillus*, yeast, an insect or insect  
25 cell, and an animal cell may be used as a host.

As *Esherichia*, *Esherichia coli* K12/DH1 [Proceedings of the National Academy of Sciences of the USA (Proc. Natl. Acad. Sci. USA), Vol. 60, 160(1968)], JM103 [Nucleic Acids Research, Vol. 9, 309(1981)], JA221 [Journal of Molecular Biology, Vol. 120, 517 (1978)], HB101 [Journal of Molecular Biology, Vol. 41, 459 (1969)], and C600 [Genetics, Vol. 39, 440 (1954)] are used.  
30

As *Bacillus*, for example, *Bacillus subtilis* MI114 [Gene, Vol. 24, 255(1983)] and 207-21 [Journal of Biochemistry, Vol. 95, 87(1984)] are used.

35 As yeasts, for example, *Saccharomyces cerevisiae* AH22, AH22R<sup>-</sup>, NA87-11A, DKD-5D and 20B-12 are used.

As insects, for example, larvae of *Bombyx* are used [Nature, Vol. 315, 592(1985)].

As insect cells, in case of virus if the virus is, for example, AcNPV, *Spondoptera frugiperda* cells (Sf cells),  
 5 *Trichoplusia ni* mesogaster-derived MG1 cells, *Trichoplusia ni* ovum-derived High Five<sup>TM</sup> cells, *Mamestra brassicae*-derived cells or *Estigmena acrea*-derived cells are used. If the virus is BmNPV, *Bombyx mori* N cells are used. As the Sf cells, for example, Sf9 cells (ATCC CRL1711), Sf21 cells are used [all by  
 10 Vaughn, J.L. et al., in Vitro, Vol. 13, 213-217(1977)].

As animal cells, for example, monkey COS-7 cells, Vero cells, Chinese hamster cell CHO, DHFR-deficient Chinese hamster cell CHO (dhfr-CHO cell), mouse L cells, mouse 3T3 cells, mouse myeloma cells, human HEK293 cells, human FL cells, 293 cells,  
 15 C127 cells, BALB3T3 cells and Sp-2/O cells are used.

A membrane fraction refers to a fraction that contains an abundance of cell membranes that are obtained by means of any of known methods after disrupting cells. Methods for cell disruption include those where cells are crushed using a  
 20 Potter-Elvehjem type homogenizer, cell disruption by Waring blender or Polytron (Kinematica AG), by ultrasound or by blowing cells out from a narrow nozzle while pressurizing using a French press.

For fractionation of cell membranes, centrifugal  
 25 fractionations such as a differential centrifugation and a fractionation density gradient centrifugation are mainly applied. For example, after cell disrupter fluid is centrifuged at a low speed (500 rpm to 3,000 rpm) for a short time (usually approx. 1 to 10 minutes), the supernatant is  
 30 centrifuged at higher speed (15,000 rpm to 30,000 rpm) usually for 30 minutes to 2 hours to obtain precipitation that is to be membrane fraction. Said membrane fraction contains an abundance of expressed G protein-coupled receptor proteins and membrane components such as cell-derived phospholipid and  
 35 membrane protein.

The amount of G protein-coupled receptor proteins in the

cells and membrane fractions that contain said G protein-coupled receptor proteins is preferably  $10^3$  to  $10^8$  molecules per cell, and optimally  $10^5$  to  $10^7$  molecules. It is noted that the more the expressed amount is, the higher is the ligand binding activity per membrane fraction (specific activity), so that a screening system with higher sensitivity can be constructed and the more specimens can be determined in the same lot.

To perform ① to ③ described above that are means for screening compounds that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor, appropriate G protein-coupled receptor fractions and labeled peptides or the like of the present invention are used. As G protein-coupled receptor fractions, G protein-coupled receptor fractions of natural type, or G protein-coupled receptor fractions of recombinant type having an equivalent activity are desirable. An equivalent activity here refers to an equivalent ligand binding activity or the like. As a labeled ligand, a labeled ligand, a labeled ligand analogous compound and the like are used. For example, ligands labeled with [ $^3\text{H}$ ], [ $^{125}\text{I}$ ], [ $^{14}\text{C}$ ] or [ $^{35}\text{S}$ ] are may be used.

More specifically, to perform screening for compounds that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins, first, the receptor preparation is prepared by suspending cells and membrane fractions that contain said G protein-coupled receptor proteins (APJ) in an appropriate buffer for screening. The buffer may be any of buffers such as phosphate buffer pH 4 to 10 (preferably pH 6 to 8) and Tris-HCl buffer, which do not inhibit binding ligands with receptors. For the purpose of reducing non-specific binding, surfactants such as CHAPS, Tween 80<sup>TM</sup> (Kao-Atlas), digitonin and deoxycholate may be added to the buffer. Moreover, for the purpose of inhibiting decomposition of receptor or the peptides or the like of the present invention, protease inhibitors such as PMSF, leupeptin, E-64 (Peptide Institute, Inc.) and

pepstatin may be added. Certain amount (5,000 cpm to 50,000 cpm) of labeled peptides or the like of the present invention is added to 0.01 ml to 10 ml of said receptor solution and  $10^{-4}$  to  $10^{-1}$   $\mu$ M of test compound are made to coexist. To know  
5 non-specific binding (NSB), reaction tubes added by largely excessive amounts of unlabeled peptides or the like of the present invention are prepared. Reactions are carried out at 0°C to 50°C, preferably at 4°C to 37°C, for 20 minutes to 24 hours, preferably, for 30 minutes to 3 hours. After reaction, it is  
10 filtrated with a glass fiber filter paper, washed with an appropriate amount of the same buffer, and the residual radioactivity in the glass fiber filter paper is measured with a liquid scintillation counter or a  $\gamma$ -counter. Candidate compounds with competitive inhibitory capacity can be selected  
15 if non-specific binding (NSB) of the compounds tested is not more than, for example, 50%, taking the count (B0 - NSB), the difference between the count without competitive substance (B0) and that of non-specific binding (NSB), as 100%.

To perform screening for compounds that may alter the  
20 binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ), cell stimulation activities through G protein-coupled receptor proteins (e.g. activities that promote or inhibit arachidonic acid liberation, acetylcholine liberation, intracellular  $\text{Ca}^{2+}$   
25 liberation, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, the variation in membrane potential, intracellular protein phosphorylation, c-fos activation or pH decrease) can be determined by using known methods or commercially available assay kits.

30 More specifically, first, cells containing G protein-coupled receptor proteins are cultured in multi-well plates. When performing screening, a fresh medium or an appropriate buffer that have no toxicity to cells are replaced  
for in advance, a test compound is added and incubated for a  
35 certain period, before cells are extracted or the supernatant is recovered to determine resulting products following

appropriate procedures. When it is difficult to assay production of a substance that is to be an indicator for cell stimulation activities (e.g. arachidonic acid) by the catabolic enzyme contained in cells, an inhibitor against said catabolic enzyme may be added to perform assay. Activities such as inhibition of cAMP production can be detected as inhibiting activities for cells of which the amount of basic production has been increased by forskolin or the like.

To perform screening by measuring cell stimulation activities, cells expressing appropriate G protein-coupled receptor proteins are required. As cells expressing the G protein-coupled receptor proteins of the present invention, recombinant G protein-coupled receptor proteins (APJ) expressed cell strain described above are desirable.

Test compounds include peptides, proteins, non-peptide compounds, synthesized compounds, fermentation products, cell extract, plant extract and animal-tissue extract, and may be either novel compounds or known compounds.

Screening kits for compounds that may alter the binding capacities of the peptides or the like of the present invention and G protein-coupled receptor proteins (APJ) are those that contain G protein-coupled receptor proteins or their salts; partial peptides of G protein-coupled receptor proteins, their amides, esters, or salts thereof; cells that contain G protein-coupled receptor proteins; or membrane fractions of cells containing G protein-coupled receptor proteins; and the peptides or the like of the present invention.

Screening kits of the present invention include the followings:

1. Screening reagents

① Screening buffer and washing buffer

Hanks' Balanced Salt Solution (Gibco) that added with 0.05% bovine serum albumin (Sigma)

It may be sterilized by filtration through a filter with 0.45  $\mu$ m pore size and stored at 4°C, or may be prepared just before use.



② G protein-coupled receptor (APJ) preparation

CHO cells expressing G protein-coupled receptor proteins (APJ) are subcultured in 12-well plates with  $5 \times 10^5$  cells per well and incubated at 37°C, 5% CO<sub>2</sub> and 95% air for 2 days.

5 ③ Labeled peptides or the like of the present invention

The peptides or the like of the present invention are labeled with [<sup>3</sup>H], [<sup>125</sup>I], [<sup>14</sup>C] or [<sup>35</sup>S], dissolved in appropriate solvent or buffer, stored at 4°C or -20°C, and diluted with assay buffer to 1 μM just before use.

10 ④ Peptides or the like of the present invention standard solution

Peptides or the like of the present invention are dissolved to 1 mM with PBS containing 0.1% bovine serum albumin (Sigma) and stored at -20°C.

15 2. Assay

① After cells expressing G protein-coupled receptor proteins (APJ) cultured in 12-well tissue culture plates are washed twice with 1 ml assay buffer, 490 μl of assay buffer is added to each well.

20 ② After adding 5 μl of 10<sup>-3</sup> to 10<sup>-10</sup> M test compound solution, 5 μl of labeled peptides or the like of the present invention is added and made reacted at room temperature for 1 hour. To know the amount of non-specific binding, 5 μl of 10<sup>-3</sup> M ligand is added instead of a test compound.

25 ③ After removing the reactant solution, wash three times with 1 ml washing buffer. The peptides or the like of the present invention bound with cells are dissolved with 0.2N NaOH-1% SDS and mixed with 4 ml of liquid scintillator (Wako Pure Chemical Industries, Ltd.).

30 ④ The radioactivity is measured by using a liquid scintillation counter (Beckman) and calculated by the following formula [数 1]

[Formula 1]

$$\text{PBM} = [(B - \text{NSB}) / (B_0 - \text{NSB})] \times 100$$

35 PMB: Percent Maximum Binding

B : a value when the specimen is added

NSB : Non-specific Binding

B0 : Maximum Binding

Compounds and their salts that are obtained by using the screening procedures or the screening kits of the present invention are compounds that alter binding (inhibit or promote binding) of the peptides or the like of the present invention with G protein-coupled receptor (APJ), or more specifically, compounds and their salts that have cell stimulation activities through G protein-coupled receptors (so-called G protein-coupled receptor agonist) or compounds that have said stimulation activities (so-called G protein-coupled receptor antagonist). Said compounds include peptides, proteins, non-peptide compounds, synthesized compounds, fermentation products, cell extract, and may be either novel compounds or known compounds.

The methods for evaluation whether it is a G protein-coupled receptor agonist or antagonist may be accordance with (i) or (ii) described below.

(i) After performing the binding assay shown in the screening procedures of ① to ③ described above to obtain compounds that alter the binding capacities of the peptides or the like of the present invention with G protein-coupled receptors (APJ) (especially, that inhibit binding), assay whether said compounds have cell stimulation activities through G protein-coupled receptors (APJ). A compound or its salt that has a cell stimulation activity is a G protein-coupled receptor agonist, while a compound or its salt that does not have said activity is a G protein-coupled receptor antagonist.

(ii) (a) A test compound is brought into contact with cells that contain G protein-coupled receptor proteins (APJ) and cell stimulation activities through G protein-coupled receptors (APJ) are determined. A compound or its salt that has a cell stimulation activity is a G protein-coupled receptor agonist. (b) Cell stimulation activities through G protein-coupled receptors (APJ) in the case where a compound that activates a G protein-coupled receptor (e.g. the peptides or the like of

the present invention or G protein-coupled receptor agonist) is brought into contact with cells that contain G protein-coupled receptor proteins (APJ), and the case where a compound that activates a G protein-coupled receptor and a test compound are brought into contact with cells that contain G protein-coupled receptor proteins (APJ) are determined and compared. A compound or its salts that can reduce cell stimulation activities by a compound that activates G protein-coupled receptor coupled receptors (APJ) is a G protein-coupled receptor antagonist.

Since said G protein-coupled receptor agonist has activities similar to the physiological activities of the peptides or the like of the present invention against G protein-coupled receptors (APJ), it is useful as a safe and low toxic pharmaceutical, as well as the peptides or the like of the present invention.

On the contrary, since G protein-coupled receptor antagonist can inhibit the physiological activities of the peptides or the like of the present invention against G protein-coupled receptors (APJ), it is useful as a safe and low toxic pharmaceuticals that inhibit said receptor activities.

Since the peptides or the like of the present invention are involved in activities of central nervous functions, circulatory functions, cardiac functions, immune functions, digestive functions, metabolic functions, or reproductive organ functions, agonists or antagonists described above can be used as therapeutic or prophylactic drugs against disorders, such as: dementia including dementia associated with senile dementia, cerebrovascular dementia, dementia associated with retroplastic diseases of the systemic degeneration type (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's disease), dementia associated with infective diseases (e.g. slow virus infections such as Creutzfeldt-Jakob disease), dementia associated with endocrine disease, metabolic disease or toxic disease (e.g. hypothyroidism, vitamin B12 deficiency disease, alcoholism, and intoxication

with various drugs, metal or organic compound), dementia associated with neoplastic diseases such (e.g. brain tumor), and dementia associated with traumatopathy (e.g. chronic subdural hematoma); depression, ADHD (minimal brain dysfunction) syndrome; disturbance of consciousness; anxiety disorder; schizophrenia; phobia, growth hormone secretion disorder (e.g. gigantism, acromegaly), hyperphagia, polyphagia, hypercholesterolemia, hyperglyceridemia, hyperlipidemia, hyperprolactinemia, hypoglycemia, hypopituitarism, hypophysial dwarfism, diabetes (e.g. diabetic complication, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy); cancer (e.g. breast cancer, lymphatic leukemia, lung cancer, bladder cancer, ovarian cancer and prostate cancer); pancreatitis, renal diseases (e.g. chronic renal failure, nephritis); Turner's syndrome; neuropathy; rheumatoid arthritis; spinal cord injury; transient ischemic attack; amyotrophic lateral sclerosis; acute myocardial infarct; spinocerebellar degeneration; fracture; injury; atopic dermatitis; osteoporosis; asthma; epilepsy; infertility; arteriosclerosis; emphysema pulmonum; pulmonary edema or hypogalactia. Also they can be applied as a sedative hypnotic, an agent that improves the nutritional status of post-operative patients, vasopressor and depressor drug.

In addition, the peptides of the present invention can be used as therapeutic or prophylactic drugs against AIDS (Acquired Immune Deficiency Syndrome) or the like.

As salts of the compounds that are obtained by using the screening procedures or the screening kits described above, for example, pharmaceutically acceptable salts are used. For example, these salts include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.

Preferable examples of salts with inorganic bases include salts with alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium salts and

magnesium salts, aluminum salts, or ammonium salts.

Preferable examples of salts with organic bases include salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine or N,N'-dibenzylethylenediamine.

Preferable examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid.

Preferable examples of salts with organic acids include salts with formic acid, acetic acid, propionic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid or benzoic acid.

Preferable examples of salts with basic amino acids include salts with arginine, lysine or ornithine.

Preferable examples of salts with acidic amino acids include salts with aspartic acid or glutamic acid.

When compounds and their salts that are obtained by using the screening procedures or the screening kits of the present invention are used as pharmaceuticals described above, they can be embodied in the same way as the case where the peptides or the like are embodied as pharmaceuticals.

In the present specification and drawings thereof, abbreviations for bases, amino acids and others used in the present specification are based on abbreviations specified by the IUPAC-IUB Commission on Biochemical Nomenclature or abbreviations in common use in the relevant fields. Some examples are given below.

When an optical isomer is present in amino acid, it is of the L-configuration, unless specifically stated.

DNA	: deoxyribonucleic acid
cDNA	: complementary deoxyribonucleic acid
A	: Adenine
T	: Thymine
G	: Guanine

	C	: Cytosine
	Y	: Thymine or Cytosine
	N	: Thymine, Cytosine, Adenine or Guanine
	R	: Adenine or Guanine
5	M	: Cytosine or Adenine
	W	: Thymine or Adenine
	S	: Cytosine or Guanine
	RNA	: Ribonucleic acid
	mRNA	: messenger ribonucleic acid
10	dATP	: deoxyadenosine triphosphate
	dTTP	: deoxythymidine triphosphate
	dGTP	: deoxyguanosine triphosphate
	dCTP	: deoxycytidine triphosphate
	ATP	: adenosine triphosphate
15	EDTA	: ethylenediaminetetraacetic acid
	SDS	: sodium dodecyl sulfate
	EIA	: enzyme immunoassay
	Gly or G	: Glycine
	Ala or A	: Alanine
20	Val or V	: Valine
	Leu or L	: Leucine
	Ile or I	: Isoleucine
	Ser or S	: Serine
	Thr or T	: Threonine
25	Cys or C	: Cysteine
	Met or M	: Methionine
	Glu or E	: Glutamic acid
	Asp or D	: Aspartic acid
	Lys or K	: Lysine
30	Arg or R	: Arginine
	His or H	: Histidine
	Phe or F	: Phenylalanine
	Tyr or Y	: Tyrosine
	Trp or W	: Tryptophan
35	Pro or P	: Proline
	Asn or N	: Asparagine

Gln or Q : Glutamine  
 pGlu : Pyroglutamic acid  
 Me : Methyl group  
 Et : Ethyl group  
 Bu : Butyl group  
 Ph : Phenyl group  
 Nle : Norleucine  
 Thi : 2-Thienylalanine  
 Phg : Phenylglycine  
 Pya (2) : 2-pyridylalanine  
 Adi (NH<sub>2</sub>) : 2-aminoadipic acid-6 amide  
 Hyp : Oxyproline (Hydroxyproline)  
 Ac-Arg : N<sup>α</sup>-acetylarginine  
 Lys (Ac) : N<sup>ε</sup>-acetyllysine  
 Lys (Me) : N<sup>ε</sup>-methyllysine  
 Lys (Tos) : N<sup>ε</sup>-tosyllysine  
 Arg (Tos) : N<sup>ε</sup>-Tosylarginine  
 Phe (Cl) : 4-Chlorophenylalanine  
 Nal (2) : 2-naphthylalanine  
 Cha : Cyclohexylalanine  
 Met (O) : Methioninesulfoxide  
 Tyr (Me) : O-Methyltyrosine  
 Tyr (I) : 3-Iodotyrosine

Substituents, protecting groups, reagents that are used in this specification are represented by symbols described below.

Tos : p-Toluenesulfonyl  
 HONB : N-hydroxy-5-norbornene-2,3-dicarboximido  
 Bzl : Benzyl  
 Z : Benzyloxycarbonyl  
 Br-Z : 2-Bromobenzyloxycarbonyl  
 Cl-z : 2-Chlorobenzyloxycarbonyl  
 Boc : t-Butyloxycarbonyl  
 HOBt : 1-Hydroxybenzotriazole  
 DCC : N,N'-Dicyclohexylcarbodiimide  
 TFA : Trifluoroacetic acid

	Fmoc	: N-9-fluorenylmethoxycarbonyl
	DNP	: Dinitrophenyl
	Bum	: tertiary butoxymethyl
	Trt	: Trityl
5	Pbf	: 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl
	HOObt	: 3-Hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine
	TFE	: trifluoroethanol
10	HOAt	: 1-hydroxy-7-azabenzotriazole
	PyBrop	: bromotris(pyrrolydino)phosphonium hexafluorophosphate
	TMS-Br	: Trimethylsilyl bromide
	TC	: Thiazolidine-4(R)-carboxamide group
15	Bom	: Benzyloxymethyl
	NMP	: N-Methylpyrrolidone
	PAM	: Phenylacetamidemethyl
	DCM	: Dichloromethane
	DMF	: N,N-Dimethylformamide
20	DIEA	: N,N-Diisopropylethylamine
	Clt	: 2-Chlorotrityl
	For	: Formyl

Sequence ID numbers in the sequence listing in this specification indicate the following sequences.

- 25 [Sequence ID No.:1] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 1 described below.
- [Sequence ID No.:2] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 2 described below.
- 30 [Sequence ID No.:3] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 3 described below.
- [Sequence ID No.:4] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 4 described below.
- [Sequence ID No.:5] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 5 described below.
- 35 [Sequence ID No.:6] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 6 described below.



[Sequence ID No.:8] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 8 described below.

[Sequence ID No.:10] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 10 described below.

[Sequence ID No.:12] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 12 described below.

[Sequence ID No.:14] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 14 described below.

[Sequence ID No.:16] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 16 described below.

[Sequence ID No.:18] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 18 described below.

35 [Sequence ID No.:19] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 19 described below.

[Sequence ID No.:20] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 20 described below.

5 [Sequence ID No.:21] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 21 described below.

[Sequence ID No.:22] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 22 described below.

10 [Sequence ID No.:23] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 23 described below.

15 [Sequence ID No.:24] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 24 described below.

[Sequence ID No.:25] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 25 described below.

20 [Sequence ID No.:26] This Sequence ID number shows the amino acid sequence of APJ.

[Sequence ID No.:27] This Sequence ID number shows the DNA sequence that codes the amino acid sequence of the Sequence ID No.:26.

25 [Sequence ID No.:28] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 26 described below.

[Sequence ID No.:29] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 27 described below.

30 [Sequence ID No.:30] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 28 described below.

35 [Sequence ID No.:31] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 29 described below.

[Sequence ID No.:32] This Sequence ID number shows the amino

acid sequence of the peptide obtained in Example 30 described below.

[Sequence ID No.:33] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 31 described below.

[Sequence ID No.:34] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 32 described below.

[Sequence ID No.:35] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 33 described below.

[Sequence ID No.:36] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 34 described below.

[Sequence ID No.:37] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 35 described below.

[Sequence ID No.:38] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 36 described below.

[Sequence ID No.:39] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 37 described below.

[Sequence ID No.:40] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 38 described below.

[Sequence ID No.:41] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 39 described below.

[Sequence ID No.:42] This Sequence ID number shows the amino acid sequence of the peptide obtained in Example 40 described below.

#### Examples

Although the present invention is hereinafter described in more detail by showing examples and experimental examples,

they are not to be construed as limitative to the scope of the present invention.

Example 1 (Production of

5 Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln  
-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-Hi  
s-Lys-Gly-Pro-Nle-Pro-Phe)

A portion of 0.25 mmol of Fmoc-Phe-O-Clt resin (0.32 mmol/g) that was obtained by introducing Fmoc-Phe-OH into commercially available 2-chlorotrityl resin (Clt resin, 1.3 mmol/g) was set in a reaction chamber of a peptide synthesizer ABI 433A to carry out solid phase synthesis by means of a Fmoc/DCC/HOBt method. As protecting groups for side chains of a Fmoc amino acid, Pbf group was used for Arg, tBu group for Ser, Boc group for Trp and Lys, Trt group for His, Asn and Gln, respectively. Other amino acids used were with side chains unprotected, to which peptide chains are introduced in order towards the N terminal, from Phe to Leu of the sequence given above to obtain the desired protected peptide resin.

After stirring 50 mg (4.45 mmol) of the resin in 1 ml of a mixture of TFA, thioanisole, m-cresol, H<sub>2</sub>O and ethanedithiol (82.5:5:5:5:2.5) at room temperature for two hours, ether was added to precipitate white powder, which was centrifuged, and then the supernatant was removed. These processes were repeated three times. The residue was extracted with water and lyophilized to obtain 23.1 mg of white powder. The obtained crude peptide was subjected to preparative chromatography with TSK GEL ODS 120T column (20 × 300 mm) and eluted for 60 minutes with a linear concentration gradient of the solution A: 0.1% TFA-water and the solution B: acetonitrile containing 0.1% TFA at A/B: 85/15 to 75/25, to collect fractions containing the desired product to yield 10.2 mg of white powder by lyophilizing.

(M+H)<sup>+</sup> by mass spectrometry: 4176.0

(calculated value: 4176.3)

HPLC elution time: 17.8 minutes

Elution condition:

Column : YMC A-301-3 (4.6 × 100 mm)

Eluant : With solution A: 0.1% TFA-water and solution B:  
acetonitrile containing 0.1% TFA, elution with a  
linear concentration gradient at A/B: 100/0 to 50/50  
(25 min.)

Flow rate: 1.0 ml/min.

Example 2 (Production of

Leu-Val-Gln-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln  
-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-Hi  
s-Lys-Gly-Pro-Nle-Pro-Tyr)

The amino acid to be introduced to 2-chlorotrityl resins  
(Clt resin, 1.3 mmol/g) in Example 1 was changed to  
Fmoc-Tyr(tBu)-OH, and synthesis and purification were carried  
out in the same manner to obtain 13.3 mg of white powder of the  
desired product by lyophilizing.

(M+H)<sup>+</sup> by mass spectrometry: 4192.0

(calculated value: 4192.3)

HPLC elution time: 16.9 minutes

Elution condition:

Column : YMC A-301-3 (4.6 × 100 mm)

Eluant : With solution A: 0.1% TFA-water and solution B:  
acetonitrile containing 0.1% TFA, elution with a  
linear concentration gradient at A/B: 100/0 to 50/50  
(25 min.)

Flow rate: 1.0 ml/minute

Example 3 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe)

A portion of 0.25 mmol of Fmoc-Gly-O-Clt resin (0.392  
mmol/g) that was obtained by introducing Fmoc-Gly-OH into  
commercially available 2-chlorotrityl resin (Clt resin, 1.3  
mmol/g) was set in a reaction chamber of a peptide synthesizer  
ABI 433A and the desired protected peptide resin was obtained  
by introducing Fmoc-Lys(Boc), Fmoc-His(Trt), Fmoc-Ser(tBu),

Fmoc-Leu, Fmoc-Arg(Pbf), Fmoc-Pro, Fmoc-Arg(Pbf) and Boc-Gln in this order by means of Fmoc/DCC/HOBt method.

After 1 g of the resin was put into 20 ml of the mixture of AcOH:TFA:DCM (1:2:7) and stirred at room temperature for two hours, the mixture was filtrated to remove the resin, evaporated to remove the solvent and crystallized to obtain 362 mg of protected peptides

(Boc-Gln-Arg(Pbf)-Pro-Arg(Pbf)-Leu-Ser(tBu)-His(Trt)-Lys(Boc)-Gly-OH).

H-Phe-OBzl·Hcl was condensed with Boc-Pro, Boc-Nle and Boc-Pro in this order to obtain 180 mg of Boc-Pro-Nle-Pro-Phe-Bzl.

50 mg of

Boc-Gln-Arg(Pbf)-Pro-Arg(Pbf)-Leu-Ser(tBu)-His(Trt)-Lys(Boc)-Gly-OH and 3.96 mg of HOAt were dissolved in 700 ml of the mixture of DCM:DMF(4:1), added with 19.7 ml of DIEA, 13.5 mg of PyBrop and 18.2 mg of H-Pro-Nle-Pro-Phe-OBzl·Hcl (prepared by treating Boc-Pro-Nle-Pro-Phe-Bzl with 4N-HCl/dioxane) while cooling with ice, and were then stirred at room temperature for one hour after removing the ice bath. After adding citric acid crystals to neutralize, the mixture was freed from the solvent by evaporation and the solid precipitated with addition of water was extracted with chloroform. This was washed with 1N hydrochloric acid, saturated sodium bicarbonate solution and saturated brine, dried with anhydrous sodium sulfate, freed from the solvent by evaporation and filtrated to collect powder by adding ether and further purified by reprecipitation from ethyl acetate and ether to obtain 56 mg of

Boc-Gln-Arg(Pbf)-Pro-Arg(Pbf)-Leu-Ser(tBu)-His(Trt)-Lys(Boc)-Gly-Pro-Nle-Pro-Phe-Obzl.

After the above product was put into the mixture of 982 µl of thioanisole, 110 µl of m-cresol, 215 µl of triisopropylsilane and 4 ml of TFA and stirred at room temperature for 90 minutes, it was added with 1.1 ml of TMS-Br, stirred for one hour while cooling with ice, and then stirred

on the water bath of 20°C another one hour after removing the ice bath. After the reaction, the reaction solution was removed by evaporation and white powder was precipitated by adding ether to the residue to be centrifuged, the supernatant was removed.

5 These processes were repeated three times. The residue was extracted with water and lyophilized to obtain white powder. Subsequently, the obtained white powder was dissolved in 80% AcOH to be heated at 70°C for 2 hours, and the solution was diluted with water and lyophilized. The obtained crude

10 peptides were subjected to preparative chromatography with TSK GEL ODS 120T column (20 × 300 mm) and eluted for a 60 minutes with a linear concentration gradient of solution A: 0.1% TFA-water and solution B: acetonitrile containing 0.1% TFA at A/B: 80/20 to 70/30, to collect fractions containing the desired product to yield 14 mg of white powder by lyophilizing.

15 (M+H)<sup>+</sup> by mass spectrometry: 1515.7

(calculated value: 1515.9)

HPLC elution time: 16.8 minutes

Elution condition:

20 Column : Wakosil 5C18T (4.6 × 100 mm)

Eluant : With solution A: 0.1% TFA-water and solution B: acetonitrile containing 0.1% TFA, elution with a linear concentration gradient at A/B: 95/5 to 45/55 (25 min.)

25 Flow rate: 1.0 ml/minute

#### Example 4 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr)

H-Phe-OBzl·HCl in Example 3 was changed to

30 H-Tyr(tBu)·Obzl.HCl, and synthesis and purification were carried out in the same manner to obtain 29 mg of white powder.

(M+H)<sup>+</sup> by mass spectrometry: 1532.0

(calculated value: 1531.9)

HPLC elution time: 14.6 minutes

35 Elution condition:

Column : Wakosil 5C18T (4.6 × 100 mm)

Eluant : With solution A: 0.1% TFA-water and solution B:  
acetonitrile containing 0.1% TFA, elution with a  
linear concentration gradient at A/B: 95/5 to 45/55  
(25 min.)

5 Flow rate: 1.0 ml/minute

Example 5 (Production of  
pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro)

10 Boc-Pro-Nle-Pro-OBzl synthesized by using H-Pro-OBzl·Hcl  
instead of H-Phe-OBzl·Hcl in Example 3 was used, and synthesis  
and purification were carried out in the same manner to obtain  
8 mg of white powder.

(M+H)<sup>+</sup> by mass spectrometry: 1368.4

(calculated value: 1368.8)

15 HPLC elution time: 13.8 minutes

Elution condition:

Column : Wakosil 5C18T (4.6 × 100 mm)

Eluant : With solution A: 0.1% TFA-water and solution B:  
acetonitrile containing 0.1% TFA, elution with a  
20 linear concentration gradient at A/B: 95/5 to 45/55  
(25 min.)

Flow rate: 1.0 ml/minute

Example 6 (Production of  
25 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle)

Boc-Pro-Nle-OBzl synthesized by using H-Nle-OBzl·Hcl in  
stead of H-Phe-OBzl·Hcl in Example 3 was used, and synthesis  
and purification were carried out in the same manner to obtain  
9 mg of white powder.

30 (M+H)<sup>+</sup> by mass spectrometry: 1272.0

(calculated value: 1271.7)

HPLC elution time: 12.9 minutes

Elution condition:

Column : Wakosil 5C18T (4.6 × 100 mm)

35 Eluant : With solution A: 0.1% TFA-water and solution B:  
acetonitrile containing 0.1% TFA, elution with a



linear concentration gradient at A/B: 95/5 to 45/55  
(25 min.)

Flow rate: 1.0 ml/minute

5 Example 7 (Production of  
Ac-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr)

10 A portion of 0.5 m mole of commercially available  
Boc-Tyr(Br-Z)-OCH<sub>2</sub>-PAM resin (0.69 m mole/g resin) was set in  
a reaction chamber of a peptide synthesizer ABI 430A, to which  
Boc-Pro, Boc-Nle, Boc-Pro, Boc-Gly, Boc-Lys(Cl-Z),  
Boc-His(Bom), Boc-Ser(Bzl), Boc-Leu, Boc-Arg(Tos), Boc-Pro  
and Boc-Arg(Tos) were introduced in this order by means of  
Boc-strategy (NMP-HOBt) peptide synthesis method, and the  
desired protected peptide resin was obtained by acetylating  
15 with acetic anhydride after removing the last Boc group.

After 0.25 g of the resin was put in 5 ml of anhydrous  
hydrogen fluoride and stirred with 0.46 g of p-cresol at 0°C  
for 60 minutes, hydrogen fluoride was removed by evaporation  
under reduced pressure and the residue was added with diethyl  
20 ether to collect the precipitate by filtration and then  
extracted with aqueous acetic acid solution. After the extract  
was sufficiently concentrated and separately extracted by  
adding distilled water and diethyl ether, of which the water  
phase was collected to lyophilize, it was dissolved in a small  
25 amount of aqueous acetic acid solution to be applied to a  
Sephadex<sup>TM</sup> G-25 column (2.0 × 80 cm) packed with this solvent  
and developed with this solvent, and the major fractions were  
collected to obtain 53 mg of white powder by lyophilizing.  
After the product was applied to a reverse-phase  
30 chromato-column (2.6 × 60 cm) and washed with 200 ml of 0.1%  
TFA aqueous solution, a linear gradient elution with 300 ml of  
0.1% TFA aqueous solution and 300 ml of 33% acetonitrile aqueous  
solution containing 0.1% TFA was carried out and fractions with  
an approximately 20% acetonitrile concentration to obtain 30  
35 mg of white powder by lyophilizing.  
(M+H)<sup>+</sup> by mass spectrometry: 1462.4

Sequence amino acids were introduced to commercially available Boc-Pro-OCH<sub>2</sub>-PAM resin in order, and synthesis and purification were carried out in the same manner as Example 7 to obtain 73 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1299.5

(calculated value: 1299.8)

Boc-Nle (0.57 mmol/g) was introduced to commercially available chloromethyl resin for peptide synthesis.

Synthesis and purification were carried out by using the above in the same manner to obtain 29 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1202.9

(calculated value: 1202.7)

Commercially available Boc-Phe-OCH<sub>2</sub>-PAM resin (0.72 m mole/g resin) was used, and Boc-Lys(Cl-Z) was changed to Boc-Lys(Ac) and Boc-Nle to Boc-Met, to which amino acids were introduced in the order of the sequence in the same manner as Example 7. Instead of the last acetylation, Z-pGlu was introduced under the same condition as each Boc-amino acid. The resin was treated with hydrogen fluoride in the same manner as Example 7 and purified to obtain 70 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1575.5

(calculated value: 1575.8)

Example 11 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Me)-Gly-Pro-Met-Pro-Phe)

Boc-Lys(Ac) in Example 10 was changed to Boc-Lys(Me-Boc), and synthesis and purification were carried out in the same manner to obtain 35 mg of white powder of the desired product.

5 (M+H)<sup>+</sup> by mass spectrometry: 1547.5

(calculated value: 1547.8)

Example 12 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Ac)-Gly-Pro-Nle-Pro-Phe)

10 Boc-Met in Example 10 was changed to Boc-Nle, and synthesis and purification were carried out in the same manner to obtain 58 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1558.1

(calculated value: 1557.9)

15 Example 13 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Me)-Gly-Pro-Nle-Pro-Phe)

Boc-Met in Example 11 was changed to Boc-Nle, and synthesis and purification were carried out in the same manner to obtain 58 mg of white powder of the desired product.

20 (M+H)<sup>+</sup> by mass spectrometry: 1529.6

(calculated value: 1529.9)

Example 14 (Production of

25 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Tos)-Gly-Pro-Nle-Pro-Phe)

Boc-Lys(Ac) in Example 12 was changed to Boc-Lys(Tos), and synthesis and purification were carried out in the same manner to obtain 60 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1670.2

30 (calculated value: 1669.9)

Example 15 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Arg(Tos)-Gly-Pro-Nle-Pro-Phe)

35 The same Fmoc-Phe-O-Clt resin as Example 1 was used, to which target sequence amino acids were introduced by using in the same manner. For protecting groups for side chains of Fmoc

amino acids, a Tos group was used only for the Arg that was introduced first and a Pbf group for other Arg, a tBu group for Ser, a Boc group for Trp and Lys, a Trt group for His, Asn and Gln. By using amino acids with side chains unprotected for other amino acids or using pGlu without protecting, synthesis and purification were carried out in the same manner as Example 1 to obtain 40 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1697.7

(calculated value: 1697.9)

#### Example 16 (Production of

pGlu-Arg-Pro-Arg-Nle-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe)

In the same manner as Example 15 and by using Pbf for all protecting groups for side chains of Arg, synthesis and purification were carried out to obtain 66 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1515.8

(calculated value: 1515.9)

#### Example 17 (Production of

pGlu-Arg-Pro-Arg-Nle-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr)

Commercially available Boc-Tyr(Br-Z)-OCH<sub>2</sub>-PAM resin (0.69 m mole/g resin) in Example 7 was used, and by changing Boc-Lys(Ac) in Example 10 to Boc-Lys(Cl-Z) and Boc-Leu to Boc-Nle, synthesis and purification were carried out in the same manner to obtain 37 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1531.6

(calculated value: 1531.9)

#### Example 18 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Thi)

Phe in Example 3 was changed to Thi, and synthesis and purification were carried out in the same manner to obtain 21 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1521.7

(calculated value: 1521.8)

Example 19 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phg)

Phe in Example 3 was changed to Phg, and synthesis and purification were carried out in the same manner to obtain 16 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1501.4

(calculated value: 1501.8)

Example 20 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Pya(2))

Phe in Example 3 was changed to Pya(2), and synthesis and purification were carried out in the same manner to obtain 25 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1516.7

(calculated value: 1516.9)

Example 21 (Production of

Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr)

Resins were treated with hydrogen fluoride without acetylation in Example 7 and purified in the same manner as Example 3 to obtain 85 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1421.0

(calculated value: 1420.8)

Example 22 (Production of

Leu-Val-Adi(NH<sub>2</sub>)-Pro-Arg-Gly-Ser-Arg-Asn-Gly-Pro-Gly-Pro-Trp-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe)

The same resin as Example 10 was used, to which Boc-amino acids were introduced in the order of the sequence by using Cl-Z group for Lys, Bom group for His, Bzl group for Ser, Tos group for Arg, and For group for Trp. This was treated with hydrogen fluoride in the presence of both p-cresol and 1,4-butanediol and purified in the same manner as Example 3 to obtain 20 mg of white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 4190.0

(calculated value: 4190.4)

Example 23 (Production of

5 Leu-Val-Lys(Ac)-Pro-Arg-Thr-Ser-Arg-Thr-Gly-Pro-Gly-Ala-Trp  
-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser  
-His-Lys-Gly-Pro-Nle-Pro-Tyr)

The same resin as Example 7 was used, to which Boc-amino  
acids were introduced in the order of the sequence, by using  
10 Ac for the first Lys only and Cl-Z group for other Lys, Bom group  
for His, Bzl group for Ser, Tos group for Arg and For group for  
Trp for protecting group for side chains of Fmoc amino acids,  
and deblocking and purification were carried out in the same  
manner as Example 22 to obtain 24 mg of white powder of the  
15 desired product.

(M+H)<sup>+</sup> by mass spectrometry: 4234.2

(calculated value: 4234.4)

Example 24 (Production of

20 Tyr-Leu-Val-Lys-Pro-Arg-Thr-Ser-Arg-Thr-Gly-Pro-Gly-Ala-Trp  
-Gln-Gly-Gly-Arg-Arg-Lys-Phe-Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser  
-His-Lys-Gly-Pro-Nle-Pro-Phe)

For protecting group for side chains of Fmoc amino acids,  
Pbf group was used for Arg, a tBu group for Ser, Thr and Tyr,  
25 a Boc group for Trp and Lys, a Trt group for His, Asn and Gln,  
and synthesis and purification were carried out in the same  
manner as Example 1 to obtain 17 mg of white powder of the desired  
product.

(M+H)<sup>+</sup> by mass spectrometry: 4344.6

30 (calculated value: 4344.5)

Example 25 (Production of

Z-pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(Ac)-Gly-Pro-Nle-Pro-Phe)

Arg(Tos) in Example 15 was changed to Lys(Ac), and pGlu  
35 to Z-pGlu, and synthesis and purification were carried out in  
the same manner to obtain 67 mg of white powder of the desired

product.

(M+H)<sup>+</sup> by mass spectrometry: 1692.2

(calculated value: 1691.9)

5 Example 26 (Production of  
Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met(O))

To commercially available Boc-Met(O)-OCH<sub>2</sub>-PAM resin (0.72  
mmole/g resin), Boc-amino acids of which a Cl-Z group was used  
for Lys, Bom group for His, Bzl group for Ser, Tos group for  
10 Arg for protecting group for side chains were introduced in the  
order of the sequence, and deblocking and purification were  
carried out in the same manner as Example 7 to obtain 19 mg of  
white powder of the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1634.9

(calculated value: 1634.9)

Example 27 (Production of  
Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr  
)

20 When the sequence of  
Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Tyr  
was introduced in the production process of the compound in  
Example 2, the resin was taken out, treated by means of  
deblocking and purified in the same manner as Example 2 to obtain  
25 the desired product.

(M+H)<sup>+</sup> by mass spectrometry: 1860.9

(calculated value: 1861.1)

HPLC elution time: 16.75 minutes

Elution condition:

30 Column : YMC ODS AM-301, S-5 mm, 120A (4.6 × 100 mm)

Eluant : With solution A: 0.1% TFA-water and solution B:  
acetonitrile containing 0.1% TFA, elution with a  
linear concentration gradient at A/B: 100/0 to  
50/50 (25 min.)

35 Flow rate: 1.0 ml/minute

## Example 28 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Phe(Cl))

Fmoc-Phe(Cl)-O-Clt resin (0.42 mmol/g) that was obtained by introducing Fmoc-Phe(Cl)-OH to a commercially available 2-chlorotrityl resin (Clc resin, 1.3 mmol/g) was used, to which amino acids were introduced in the order of the sequence in the order of the sequence in the same manner as Example 15, and deblocking and purification were carried out to obtain the desired compound.

(M+H)<sup>+</sup> by mass spectrometry: 1471.0

(calculated value: 1470.7)

HPLC elution time: 19.39 minutes (Elution condition: the same as Example 27)

## Example 29 (Production of

pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe(Cl))

The desired product was obtained in the same manner as Example 28.

(M+H)<sup>+</sup> by mass spectrometry: 1567.7

(calculated value: 1567.8)

HPLC elution time: 19.81 minutes (Elution condition: the same as Example 27)

## Example 30 (Production of

Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Nal(2))

Fmoc-Nal(2)-O-Clc resin (0.45 mmol/g) that was obtained by introducing Fmoc-Nal(2)-OH to a commercially available 2-chlorotrityl resin (Clc resin, 1.3 mmol/g) was used, to which amino acids were introduced in the order of the sequence in the order of the sequence in the same manner as Example 15, and deblocking and purification were carried out to obtain the desired compound.

(M+H)<sup>+</sup> by mass spectrometry: 1472.6

(calculated value: 1472.8)

HPLC elution time: 20.48 minutes (Elution condition: the same as Example 27)



Example 31 (Production of  
Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Nal(2))

The desired product was obtained in the same manner as  
Example 30.

(M+H)<sup>+</sup> by mass spectrometry: 1375.5

(calculated value: 1375.7)

HPLC elution time: 20.35 minutes (Elution condition: the same  
as Example 27)

Example 32 (Production of  
Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe(Cl))

Fmoc-Phe(Cl)-O-Clt resin (0.42 mmol/g) was used, and the  
desired product was obtained in the same manner as Example 28.

(M+H)<sup>+</sup> by mass spectrometry: 1456.5

(calculated value: 1456.7)

HPLC elution time: 19.71 minutes (Elution condition: the same  
as Example 27)

Example 33 (Production of  
Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Phe(Cl))

The desired product was obtained in the same manner as  
Example 32.

(M+H)<sup>+</sup> by mass spectrometry: 1359.6

(calculated value: 1359.7)

HPLC elution time: 19.32 minutes (Elution condition: the same  
as Example 27)

Example 34 (Production of  
Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Cha)

Fmoc-Cha-O-Clt resin (0.49 mmol/g) that was obtained by  
introducing Fmoc-Cha-OH to a commercially available  
2-chlorotrityl resin (Clt resin, 1.3 mmol/g) was used, and the  
desired product was obtained in the same manner as Example 31.

(M+H)<sup>+</sup> by mass spectrometry: 1331.7

(calculated value: 1331.8)

HPLC elution time: 19.46 minutes (Elution condition: the same as Example 27)

Example 35 (Production of

5 pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Cha-Pro-Phe)

Fmoc-Cha-O-Clt resin (0.32 mmol/g) was used, and the desired product was obtained in the same manner as Example 28. (M+H)<sup>+</sup> by mass spectrometry: 1555.8

(calculated value: 1555.9)

10 HPLC elution time: 21.35 minutes (Elution condition: the same as Example 27)

Example 36 (Production of

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Cha)

15 The desired product was obtained in the same manner as Example 34.

(M+H)<sup>+</sup> by mass spectrometry: 1640.7

(calculated value: 1640.9)

20 Example 37 (Production of

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe (Cl))

Fmoc-Phe(Cl)-O-Clt resin (0.42 mmol/g) was used, and the desired product was obtained in the same manner as Example 27.

25 (M+H)<sup>+</sup> by mass spectrometry: 1897.5

(calculated value: 1897.7)

Example 38 (Production of

30 Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Nle-Gly-Pro-Met-Pro-Phe (Cl))

The desired product was obtained in the same manner as Example 37.

(M+H)<sup>+</sup> by mass spectrometry: 1882.3

(calculated value: 1882.6)

35

Example 39 (Production of

Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Nle-Gly-Pro-Met-Pro-Tyr  
(I))

Fmoc-Tyr(I)-O-Clt resin (0.31 mmol/g) that was obtained  
by introducing Fmoc-Tyr(I)-OH to a commercially available  
2-chlorotrityl resin (Clt resin, 1.3 mmol/g) was used, and the  
desired product was obtained in the same manner as Example 38.  
(M+H)<sup>+</sup> by mass spectrometry: 1989.7

(calculated value: 1989.9)

Example 40 (Production of  
Arg-Arg-Gln-Arg-Pro-Arg-Leu-Ser-His-Nle-Gly-Pro-Met-Pro-Tyr  
(Me))

Fmoc-Tyr(Me)-O-Clt resin (0.39 mmol/g) that was obtained  
by introducing Fmoc-Tyr(Me)-OH to a commercially available  
2-chlorotrityl resin (Clt resin, 1.3 mmol/g) was used, and the  
desired product was obtained in the same manner as Example 38.  
(M+H)<sup>+</sup> by mass spectrometry: 1878.1

(calculated value: 1878.3)

Experimental example 1

Each of peptides in Examples 3 and 4, and the corresponding  
natural peptide to the compound in Example 1 (a peptide of which  
Met was substituted for Nle, a non-natural amino acid) was  
dissolved with sterile distilled water to the concentration of  
 $1 \times 10^{-3}$  M, and prepared by serial dilution using a medium  
containing 0.1% BSA for site sensor. A10 receptor cDNA  
introduced CHO cells prepared in the same manner as WO 99/33976  
(Japanese Patent Application No. 220853-1998) were set in a  
workstation of a site-sensor, and diluted solution of the  
peptide was allowed to react with the cells 1 minute 2 seconds  
by switching channels to introduce the solution to one of the  
channels for the site sensor after the acidification rate of  
each cell became steady. Changes in acidification rate at the  
point of the maximum reaction of the cells were calculated by  
setting the value at the basal level as 100%, and the results  
are shown in Figure 1.

Experimental example 2 Assay on the suppression activity on Forskolin stimulated cAMP production

Six cells of CHO-A10 clone described in Example 7 in WO 99/33976 (Japanese Patent Application No. 220853-1998) were inoculated in 24-well tissue culture plates with  $3 \times 10^5$  cells per well and were cultured overnight. 0.2 mM 3-isobutyl-1-methylxanthine (IBMX) and Hank's balanced salt solution (HBSS) containing 0.05% bovine serum albumin were prepared as an assay buffer, each well was washed with 500  $\mu$ l of the assay buffer twice, and preincubation was carried out at 37°C for 30 minutes. Subsequently, after washing with 500  $\mu$ l of the assay buffer once, 500  $\mu$ l each of the sample dissolved in the assay buffer added with 1  $\mu$ M of forskolin were put into each well to incubate at 37°C for 30 minutes. Wells incubated with assay buffer added with no forskolin were prepared to know the basic cAMP production of cells (basal level), and similarly, wells incubated with assay buffer added with forskolin were also prepared to know the maximum cAMP production with stimulation of forskolin (maximum level). After completion of incubation, each well was washed with 500  $\mu$ l of the assay buffer once, added with 500  $\mu$ l of the lysis buffer IB included in the cAMP EIA system (Amersham Pharmacia Biotech) and extraction of cAMP was carried out. Following the prescription for the kit, a portion of 100  $\mu$ l each of the extracts was used to assay. The level of suppression activity on cAMP production was calculated by taking the difference between the maximum level and cAMP in the wells that was added with a sample (amount of the suppression of cAMP production), and by taking it as a percentage relative to the increased production (difference between maximum level and basal level) in cAMP associated with forskolin stimulation, and  $EC_{50}$  was determined based on the dose response curve.

Activities of compounds in examples determined by using the method in experimental Example 2 are given in Table 1.

Table 1

Compounds	EC <sub>50</sub> (nM)
Compound in Example 2	0.41
Compound in Example 3	0.28
Compound in Example 4	0.19
Compound in Example 10	0.25
Compound in Example 29	0.48
Compound in Example 30	0.28
Compound in Example 31	0.30
Compound in Example 32	0.20
Compound in Example 33	0.10
Compound in Example 34	0.37
Compound in Example 35	0.34
Compound in Example 36	0.16
Compound in Example 37	0.14
Compound in Example 38	0.35
Corresponding natural peptide to the compound (a peptide of which Met was substituted for Nle, a non-natural amino acid) in Example 1	0.52

#### INDUSTRIAL APPLICABILITY


5 Since the peptides or the like of the present invention are involved in activities of central nervous functions, circulatory functions, cardiac functions, immune functions, digestive functions, metabolic functions, or reproductive organ functions, agonists or antagonists described above can be used as therapeutic or prophylactic drugs against disorders, 10 such as: dementia including dementia associated with senile dementia, cerebrovascular dementia, dementia associated with retroplastic diseases of the systemic degeneration type (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease,

Huntington's disease), dementia associated with infective diseases (e.g. slow virus infections such as Creutzfeldt-Jakob disease), dementia associated with endocrine disease, metabolic disease or toxic disease (e.g. hypothyroidism, vitamin B12 deficiency disease, alcoholism, and intoxication with various drugs, metal or organic compound), dementia associated with neoplastic diseases such (e.g. brain tumor), and dementia associated with traumatopathy (e.g. chronic subdural hematoma); depression, ADHD (minimal brain dysfunction) syndrome; disturbance of consciousness; anxiety disorder; schizophrenia; phobia, growth hormone secretion disorder (e.g. gigantism, acromegaly), hyperphagia, polyphagia, hypercholesterolemia, hyperglyceridemia, hyperlipidemia, hyperprolactinemia, hypoglycemia, hypopituitarism, hypophysial dwarfism, diabetes (e.g. diabetic complication, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy); cancer (e.g. breast cancer, lymphatic leukemia, lung cancer, bladder cancer, ovarian cancer and prostate cancer); pancreatitis, renal diseases (e.g. chronic renal failure, nephritis); Turner's syndrome; neuropathy; rheumatoid arthritis; spinal cord injury; transient ischemic attack; amyotrophic lateral sclerosis; acute myocardial infarct; spinocerebellar degeneration; fracture; injury; atopic dermatitis; osteoporosis; asthma; epilepsy; infertility; arteriosclerosis; emphysema pulmonum; pulmonary edema or hypogalactia. Also they can be applied as a sedative hypnotic, an agent that improves the nutritional status of post-operative patients, vasopressor and depressor drug.

In addition, the peptides of the present invention can be used as therapeutic or prophylactic drugs against AIDS (Acquired Immune Deficiency Syndrome) or the like.

## CLAIMS

1. A peptide represented by the formula:



5 [wherein  $X^1$  represents a hydrogen atom or an amino acid residue comprising 1 to 25 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain;  $X^2$  represents a neutral amino acid residue having a side chain which may be substituted;  $X^3$  represents a neutral amino  
10 acid residue having a side chain which may be substituted, an aromatic amino acid residue having a side chain which may be substituted or a basic amino acid residue having a side chain which may be substituted;  $X^4$  represents a bond or a neutral or aromatic amino acid residue having a side chain which may be  
15 substituted;  $X^5$  represents ① an amino acid residue having a side chain which may be substituted or an amino acid derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group, ② a hydroxyl group or ③ a dipeptide chain comprising an amino acid residue having a side chain which  
20 may be substituted and an amino acid residue having a side chain which may be substituted, bound together, or a peptide derivative with the C-terminal carboxyl group reduced to a hydroxymethyl group or a formyl group; and a side chain in each amino acid residue in -Arg-Pro-Arg-, -Ser-His- or -Gly-Pro- in  
25 the formula may be substituted; except the case where  $X^2$  represents Leu,  $X^3$  represents Lys,  $X^4$  represents Met,  $X^5$  represents ① Pro or ② Pro-Phe, and -Arg-Pro-Arg- in the formula represents unsubstituted -Arg-Pro-Arg-, -Ser-His- represents unsubstituted -Ser-His-, and -Gly-Pro- represents  
30 unsubstituted -Gly-Pro-], or an ester thereof, or a salt thereof.

2. A peptide, as claimed in claim 1, wherein  $X^1$  is an amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

35 3. A peptide as claimed in claim 1, wherein  $X^1$  is pGlu which may be substituted or Gln having a side chain which may be

substituted, or an ester thereof or a salt thereof.

4. A peptide as claimed in claim 1, wherein  $X^1$  is represented by the formula  $Y^1-Y^2$  (wherein  $Y^1$  represents an amino acid residue comprising 1 to 17 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain, and  $Y^2$  represents an amino acid residue comprising 1 to 8 amino acids each of which, whether identical or not, has a side chain which may be substituted, or a peptide chain), or an ester thereof or a salt thereof.

5. A peptide as claimed in claim 4, wherein  $Y^2$  is a peptide chain represented by ① the formula  $B^1-B^2-B^3-B^4-B^5-B^6-B^7-B^8$  (wherein each of  $B^1$  through  $B^8$ , whether identical or not, represents an amino acid residue having a side chain which may be substituted), ② the formula  $B^2-B^3-B^4-B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ③ the formula  $B^3-B^4-B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ④ the formula  $B^4-B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ⑤ the formula  $B^5-B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ⑥ the formula  $B^6-B^7-B^8$  (wherein the symbols have the same definitions as those given above), ⑦ the formula  $B^7-B^8$ , (wherein the symbols have the same definitions as those given above), or ⑧ the formula  $B^8$  (wherein  $B^8$  has the same definition as that given above), or an ester thereof or a salt thereof.

6. A peptide as claimed in claim 5, wherein  $B^1$  is a neutral amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

7. A peptide as claimed in claim 6, wherein  $B^1$  is Gly which may be substituted, or an ester thereof or a salt thereof.

8. A peptide as claimed in claim 5, wherein each of  $B^2$ ,  $B^3$  and  $B^4$ , whether identical or not, is a basic amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

9. A peptide as claimed in claim 5, wherein  $B^5$  is an amino acid residue having an aromatic side chain, or an ester thereof or



a salt thereof.

10. A peptide as claimed in claim 5, wherein each of B<sup>6</sup> and B<sup>7</sup>, whether identical or not, is a basic amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

11. A peptide as claimed in claim 5, wherein B<sup>8</sup> is Gln having a side chain which may be substituted, or an ester thereof or a salt thereof.

12. A peptide as claimed in claim 4, wherein Y<sup>1</sup> is an amino acid residue or peptide chain represented by (a) the formula

A<sup>1</sup>-A<sup>2</sup>-A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein each of A<sup>1</sup> to A<sup>17</sup>, whether identical or not, represents an amino acid residue having a side chain which may be substituted), (b)

the formula A<sup>2</sup>-A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup>

(wherein the symbols have the same definitions as those given above), (c) the formula

A<sup>3</sup>-A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same definitions as those given above), (d) the formula A<sup>4</sup>-A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup>

(wherein the symbols have the same definitions as those given above), (e) the formula

A<sup>5</sup>-A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein each symbols have the same definitions as those given above), (f) the formula A<sup>6</sup>-A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the

symbols have the same definitions as those given above), (g) the formula A<sup>7</sup>-A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same definitions as those given above), (h)

the formula A<sup>8</sup>-A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same definitions as those given above), (i)

the formula A<sup>9</sup>-A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same definitions as those given above), (j) the formula A<sup>10</sup>-A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same

definitions as those given above), (k) the formula

A<sup>11</sup>-A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same

definitions as those given above), (l) the formula

A<sup>12</sup>-A<sup>13</sup>-A<sup>14</sup>-A<sup>15</sup>-A<sup>16</sup>-A<sup>17</sup> (wherein the symbols have the same

definitions as those given above), (m) the formula  $A^{13}-A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (n) the formula  $A^{14}-A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above),  
 5 (o) the formula  $A^{15}-A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), (p) the formula  $A^{16}-A^{17}$  (wherein the symbols have the same definitions as those given above), or (q)  $A^{17}$  (wherein  $A^{17}$  has the same definition as that given above), or an ester thereof or a salt thereof.

10 13. An amino acid residue or peptide as claimed in claim 12, wherein  $A^1$  is an amino acid residue having an aromatic side chain, or an ester thereof or a salt thereof.

14. A peptide as claimed in claim 12, wherein  $A^2$  and  $A^3$  are neutral amino acid residues having a side chain which may be substituted,  
 15 or an ester thereof or a salt thereof.

15. A peptide as claimed in claim 12, wherein  $A^4$  is a neutral or a basic L-amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

16. A peptide as claimed in claim 12, wherein  $A^5$  is Pro having  
 20 a side chain which may be substituted, or an ester thereof or a salt thereof.

17. A peptide as claimed in claim 12, wherein each of  $A^6$  and  $A^9$ , whether identical or not, is a basic amino acid residue having a side chain which may be substituted, or an ester thereof  
 25 or a salt thereof.

18. A peptide as claimed in claim 12, wherein each of  $A^7$  and  $A^{10}$ , whether identical or not, is an amino acid residue having a hydroxy group in a side chain thereof or a neutral amino acid residue having a side chain which may be substituted, or an ester  
 30 thereof or a salt thereof.

19. A peptide as claimed in claim 12, wherein  $A^8$  is an amino acid residue having a hydroxy group in a side chain thereof, or an ester thereof or a salt thereof.

20. A peptide as claimed in claim 12, wherein  $A^8$  is Ser, Pro  
 35 or Hyp, or an ester thereof or a salt thereof.

21. A peptide as claimed in claim 12, wherein  $A^{10}$  is an amino

acid residue having a hydroxy group in a side chain thereof, or an ester thereof or a salt thereof.

22. A peptide as claimed in claim 12, wherein A<sup>11</sup> through A<sup>14</sup>, whether identical or not, is a neutral amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

23. A peptide as claimed in claim 12, wherein A<sup>15</sup> is an amino acid residue having an aromatic side chain, or an ester thereof or a salt thereof.

24. A peptide as claimed in claim 23, wherein A<sup>15</sup> is Trp, or an ester thereof or a salt thereof.

25. An amino acid residue or peptide as claimed in claim 12, wherein each of A<sup>16</sup> and A<sup>17</sup>, whether identical or not, represents a neutral amino acid residue having a side chain which may be substituted, or an ester thereof or a salt thereof.

26. A pharmaceutical containing a peptide, as claimed in claim 1, or an ester thereof or a salt thereof.

27. A pharmaceutical as claimed in claim 26 which is a central nervous function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive function regulator, a metabolic function regulator or a reproductive organ function regulator.

28. A pharmaceutical as claimed in claim 26 which is an agonist of a protein containing an amino acid sequence shown by Sequence ID No.:26 or a salt thereof.

The present invention relates to novel peptides that are recognized by G protein-coupled receptor proteins.

The peptides of the present invention may be used for ① development of receptor binding assay system using the expression system of recombinant receptor proteins and screening of candidate compounds for potent pharmaceutical products and ② development of pharmaceuticals such as a central nervous function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive function regulator, a metabolic function regulator or a reproductive organ function regulator.

<110> Takeda Chemical Industries, Ltd.

<120> Peptide derivative

<130> 2549W00P

<150> JP 10-271626

<151> 1998-9-25

&lt;160&gt; 42

<210> 1

<211> 36

&lt;212&gt; PRT

### <213> Artificial Sequence

<223> Xaa means Nle.

 $\langle 400 \rangle$  1

Leu Val Gln Pro Arg Gly Ser Arg Asn Gly Pro Gly Pro Trp Gln Gly

1

5

10

15

Gly Arg Arg Lys Phe Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly

20

25

30

Pro Xaa Pro Phe

35

<210> 2

<211> 36

&lt;212&gt; PRT

### <213> Artificial Sequence

<223> Xaa means Nle.

· <400> 2

Leu Val Gln Pro Arg Gly Ser Arg Asn Gly Pro Gly Pro Trp Gln Gly

<223> Xaa on the 1st position means pGlu, Xaa on the 11th position means

Nle.

<400> 5

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Xaa Pro

1                      5                      10

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 11th position means

Nle.

<400> 6

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Xaa

1                      5                      10

<210> 7

<211> 12

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means Ac-Arg, Xaa on the 10th position means

Nle.

<400> 7

Xaa Pro Arg Leu Ser His Lys Gly Pro Xaa Pro Tyr

1                      5                      10

<210> 8

<211> 11

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means Ac-Arg, Xaa on the 10th position means

Nle.

<400> 8

Xaa Pro Arg Leu Ser His Lys Gly Pro Xaa Pro

1                      5                      10

<210> 9

<211> 10

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means Ac-Arg, Xaa on the 10th position means

Nle.

<400> 9

Xaa Pro Arg Leu Ser His Lys Gly Pro Xaa

1                      5                      10

<210> 10

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 8th position means

Lys(Ac).

<400> 10

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Met Pro Phe

1                      5                      10

<210> 11

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 8th position means



Lys(Me).

<400> 11

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Met Pro Phe

1

5

10

<210> 12

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 8th position means Lys(Ac), Xaa on the 11th position means Nle.

<400> 12

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Xaa Pro Phe

1

5

10

<210> 13

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 8th position means Lys(Me), Xaa on the 11th position means Nle.

<400> 13

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Xaa Pro Phe

1

5

10

<210> 14

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 8th position means Lys(Tos), Xaa on the 11th position means Nle.

&lt;400&gt; 14

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Xaa Pro Phe

1

5

10

&lt;210&gt; 15

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 8th position means Arg(Tos), Xaa on the 11th position means Nle.

&lt;400&gt; 15

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Xaa Pro Phe

1

5

10

&lt;210&gt; 16

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 5th position means Nle, Xaa on the 11th position means Nle.

&lt;400&gt; 16

Xaa Arg Pro Arg Xaa Ser His Lys Gly Pro Xaa Pro Phe

1

5

10

&lt;210&gt; 17

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 5th position means Nle, Xaa on the 11th position means Nle.

<400> 17

Xaa Arg Pro Arg Xaa Ser His Lys Gly Pro Xaa Pro Tyr

1                      5                      10

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 11th position means Nle, Xaa on the 13th position means Thi.

<400> 18

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Xaa Pro Xaa

1                      5                      10

<210> 19

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 11th position means Nle, Xaa on the 13th position means Phg.

<400> 19

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Xaa Pro Xaa

1                      5                      10

<210> 20

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 11th position means Nle, Xaa on the 13th position means Pya(2).

<400> 20

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Xaa Pro Xaa

1                      5                      10

<210> 21

<211> 12

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 10th position means Nle.

<400> 21

Arg Pro Arg Leu Ser His Lys Gly Pro Nle Pro Tyr

1                      5                      10

<210> 22

<211> 36

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 3rd position means Adi(NH<sub>2</sub>), Xaa on the 34th position means Nle.

<400> 22

Leu Val Xaa Pro Arg Gly Ser Arg Asn Gly Pro Gly Pro Trp Gln Gly

1                      5                      10                      15

Gly Arg Arg Lys Phe Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly

20                      25                      30

Pro Xaa Pro Phe

35

<210> 23

<211> 36

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 3rd position means Lys(Ac), Xaa on the 34th position means

<400> 23

1                      5                      10                      15

20                      25                      30

35

&lt;211&gt; 37

### <213> Artificial Sequence

<400> 24

1                      5                      10                      15

20                      25                      30

35

&lt;211&gt; 13

### <213> Artificial Sequence

Lys(Ac), Xaa on the 11th position means Nle.

<400> 25

Xaa Arg Pro Arg Leu Ser His Xaa Gly Pro Xaa Pro Phe

1 5 10

<210> 26

<211> 380

<212> PRT

<213> Unknown

<220>

<223>

<400> 26

Met Glu Glu Gly Gly Asp Phe Asp Asn Tyr Tyr Gly Ala Asp Asn Gln  
1 5 10 15  
Ser Glu Cys Glu Tyr Thr Asp Trp Lys Ser Ser Gly Ala Leu Ile Pro  
20 25 30  
Ala Ile Tyr Met Leu Val Phe Leu Leu Gly Thr Thr Gly Asn Gly Leu  
35 40 45  
Val Leu Trp Thr Val Phe Arg Ser Ser Arg Glu Lys Arg Arg Ser Ala  
50 55 60  
Asp Ile Phe Ile Ala Ser Leu Ala Val Ala Asp Leu Thr Phe Val Val  
65 70 75 80  
Thr Leu Pro Leu Trp Ala Thr Tyr Thr Tyr Arg Asp Tyr Asp Trp Pro  
85 90 95  
Phe Gly Thr Phe Phe Cys Lys Leu Ser Ser Tyr Leu Ile Phe Val Asn  
100 105 110  
Met Tyr Ala Ser Val Phe Cys Leu Thr Gly Leu Ser Phe Asp Arg Tyr  
115 120 125  
Leu Ala Ile Val Arg Pro Val Ala Asn Ala Arg Leu Arg Leu Arg Val  
130 135 140  
Ser Gly Ala Val Ala Thr Ala Val Leu Trp Val Leu Ala Ala Leu Leu  
145 150 155 160

Ala Met Pro Val Met Val Leu Arg Thr Thr Gly Asp Leu Glu Asn Thr  
 165 170 175  
 Thr Lys Val Gln Cys Tyr Met Asp Tyr Ser Met Val Ala Thr Val Ser  
 180 185 190  
 Ser Glu Trp Ala Trp Glu Val Gly Leu Gly Val Ser Ser Thr Thr Val  
 195 200 205  
 Gly Phe Val Val Pro Phe Thr Ile Met Leu Thr Cys Tyr Phe Phe Ile  
 210 215 220  
 Ala Gln Thr Ile Ala Gly His Phe Arg Lys Glu Arg Ile Glu Gly Leu  
 225 230 235 240  
 Arg Lys Arg Arg Arg Leu Leu Ser Ile Ile Val Val Leu Val Val Thr  
 245 250 255  
 Phe Ala Leu Cys Trp Met Pro Tyr His Leu Val Lys Thr Leu Tyr Met  
 260 265 270  
 Leu Gly Ser Leu Leu His Trp Pro Cys Asp Phe Asp Leu Phe Leu Met  
 275 280 285  
 Asn Ile Phe Pro Tyr Cys Thr Cys Ile Ser Tyr Val Asn Ser Cys Leu  
 290 295 300  
 Asn Pro Phe Leu Tyr Ala Phe Phe Asp Pro Arg Phe Arg Gln Ala Cys  
 305 310 315 320  
 Thr Ser Met Leu Cys Cys Gly Gln Ser Arg Cys Ala Gly Thr Ser His  
 325 330 335  
 Ser Ser Ser Gly Glu Lys Ser Ala Ser Tyr Ser Ser Gly His Ser Gln  
 340 345 350  
 Gly Pro Gly Pro Asn Met Gly Lys Gly Gly Glu Gln Met His Glu Lys  
 355 360 365  
 Ser Ile Pro Tyr Ser Gln Glu Thr Leu Val Val Asp  
 370 375 380

<400> 27

&lt;210&gt; 28



&lt;212&gt; PRT

<223> Xaa on the 13th position means Met(0). ,

Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Xaa

<210> 29

&lt;211&gt; 15

&lt;212&gt; PRT

### <213> Artificial Sequence

<223> Xaa on the 13th position means Nle.

<400> 29

Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Xaa Pro Tyr

1                      5                      10                      15

<210> 30

&lt;211&gt; 12

&lt;212&gt; PRT

### <213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 12th position means Phe(C1).

<400> 30

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Met Xaa

1                      5                      10            12

<210> 31

&lt;211&gt; 13

&lt;212&gt; PRT

### <213> Artificial Sequence

<400> 31

1                      5                      10                      13

&lt;211&gt; 12

### <213> Artificial Sequence

&lt;400&gt; 32

1                      5                      10            12

&lt;211&gt; 11

### <213> Artificial Sequence

<400> 33

1                      5                      10    11

<211> 13

### <213> Artificial Sequence

<400> 34

Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Xaa

1                      5                      10                      13

<210> 35

<211> 11

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 11th position means Phe(C1).

<400> 35

Arg Pro Arg Leu Ser His Lys Gly Pro Met Xaa

1                      5                      10    11

<210> 36

<211> 11

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 11th position means Cha.

<400> 36

Arg Pro Arg Leu Ser His Lys Gly Pro Met Xaa

1                      5                      10    11

<210> 37

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 1st position means pGlu, Xaa on the 11th position means Cha.

<400> 37

Xaa Arg Pro Arg Leu Ser His Lys Gly Pro Xaa Pro Phe

1                      5                      10                      13

<210> 38

<211> 13

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 13th position means Cha.

<400> 38

Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Xaa

1                      5                      10                      13

<210> 39

<211> 15

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 15th position means Phe(C1).

<400> 39

Arg Arg Gln Arg Pro Arg Leu Ser His Lys Gly Pro Met Pro Xaa

1                      5                      10                      15

<210> 40

<211> 15

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 10th position means Nle, Xaa on the 15th position means Phe(C1).

<400> 40

Arg Arg Gln Arg Pro Arg Leu Ser His Xaa Gly Pro Met Pro Xaa

1                      5                      10                      15

<210> 41

<211> 15

<212> PRT

<213> Artificial Sequence

<223> Xaa on the 10th position means Nle, Xaa on the 15th position means

<400> 41

1                      5                      10                      15

&lt;211&gt; 15


### <213> Artificial Sequence

Tyr(Me).

Arg Arg Gln Arg Pro Arg Leu Ser His Nle Gly Pro Met Pro Xaa

1
5
10
15

Figure 1



254905

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Declaration and Power of Attorney for Patent Application

### 特許出願宣言書及び委任状

### Japanese Language Declaration

### 日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that.

私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PEPTIDE DERIVATIVE

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked:

☐ \_\_\_\_\_ の日に出願され、  
この出願の米国出願番号またはPCT国際出願番号は、  
\_\_\_\_\_ であり、且つ  
\_\_\_\_\_ の日に補正された出願（該当する場合）

☒ was filed on September 24, 1999  
as United States Application Number or  
PCT International Application Number  
PCT/JP99/05216 and was amended on  
\_\_\_\_\_ (if applicable).

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above

私は、連邦規則法典第37編規則1.56に定義されている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# Japanese Language Declaration (日本語宣言書)

委任状： 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び／または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number)

Philippe Y. RIESEN (Reg. No. 35,657), Mark CHAO (Reg. No. 37,293)

書類送付先

Send Correspondence to:

Customer No. 23,115

直通電話連絡先：(氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark CHAO  
Takeda Pharmaceuticals America, Inc.  
Phone:(847)383-3372 Fax:(847)383-3481

唯一または第一発明者氏名

Full name of sole or first inventor

Chieko KITADA

発明者の署名

日付

Inventor's signature

Date

Chieko Kitada

March 13, 2001

住所

2-8, Minamikoyochi 1-cho, Sakai-shi, OSAKA 590-0073 JAPAN

Residence

JPX

国籍

Citizenship

Japan

郵便の宛先

Takeda Chemical Industries, Ltd. (IPD)  
17-85, Jusohonmachi 2-chome, Yodogawa-ku, OSAKA 532-8686 JAPAN

Post Office Address

第二共同発明者がある場合、その氏名

Full name of second joint inventor, if any

Shuji HINUMA

第二共同発明者の署名

日付

Second inventor's signature

Date

Shuji Hinuma

March 13, 2001

住所

7-9-1402, Kasuga 1-chome, Tsukuba-shi, IBARAKI 305-0821 JAPAN

Residence

JPX

国籍

Citizenship

Japan

郵便の宛先

Takeda Chemical Industries, Ltd. (IPD)  
17-85, Jusohonmachi 2-chome, Yodogawa-ku, OSAKA 532-8686 JAPAN

Post Office Address

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Japanese Language Declaration  
(日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者証の出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)-(d)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者証の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed

Prior Foreign Application(s)  
外国での先行出願

Priority Not Claimed  
優先権主張なし

10-271626

Japan

25/09/1998

(Number)  
(番号)

(Country)  
(国名)

(Day/Month/Year Filed)  
(出願日/月/年)

☐

(Number)  
(番号)

(Country)  
(国名)

(Day/Month/Year Filed)  
(出願日/月/年)

☐

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編第119条(e)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第35編第112条第1段に規定された態様で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関わる重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Status: Patented, Pending, Abandoned)  
(現況: 特許許可、係属中、放棄)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Status: Patented, Pending, Abandoned)  
(現況: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.